<article xmlns:ns0="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0221828</article-id>
<article-id pub-id-type="publisher-id">PONE-D-19-17293</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Mental health and psychiatry</subject><subj-group><subject>Dementia</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Dementia</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Neurodegenerative diseases</subject><subj-group><subject>Alzheimer's disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Animal studies</subject><subj-group><subject>Experimental organism systems</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Mouse models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Mouse models</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Animal studies</subject><subj-group><subject>Experimental organism systems</subject><subj-group><subject>Animal models</subject><subj-group><subject>Mouse models</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Diet</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Nutrition</subject><subj-group><subject>Diet</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Carbohydrate metabolism</subject><subj-group><subject>Glucose metabolism</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Metabolism</subject><subj-group><subject>Metabolites</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Microbial genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Pharmacokinetics</subject><subj-group><subject>Drug metabolism</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Dietary inulin alters the gut microbiome, enhances systemic metabolism and reduces neuroinflammation in an <italic>APOE4</italic> mouse model</article-title>
<alt-title alt-title-type="running-head">Inulin alters gut microbiome and metabolism in <italic>APOE4</italic> mice</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Hoffman</surname>
<given-names>Jared D.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; original draft</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Yanckello</surname>
<given-names>Lucille M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Chlipala</surname>
<given-names>George</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; original draft</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Hammond</surname>
<given-names>Tyler C.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>McCulloch</surname>
<given-names>Scott D.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Parikh</surname>
<given-names>Ishita</given-names>
</name>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff006"><sup>6</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Sun</surname>
<given-names>Sydney</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<name name-style="western">
<surname>Morganti</surname>
<given-names>Josh M.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff007"><sup>7</sup></xref>
</contrib>
<contrib contrib-type="author" ns0:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2781-359X</contrib-id>
<name name-style="western">
<surname>Green</surname>
<given-names>Stefan J.</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" ns0:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5197-2219</contrib-id>
<name name-style="western">
<surname>Lin</surname>
<given-names>Ai-Ling</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Investigation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Resources</role>
<role content-type="http://credit.casrai.org/">Software</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Validation</role>
<role content-type="http://credit.casrai.org/">Visualization</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; original draft</role>
<role content-type="http://credit.casrai.org/">Writing &#8211; review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
<xref ref-type="aff" rid="aff008"><sup>8</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Pharmacology and Nutritional Science, University of Kentucky, Lexington, Kentucky, United States of America</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Research Resources Center, University of Illinois at Chicago, Chicago, Illinois, United States of America</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Neuroscience, University of Kentucky, Lexington, Kentucky, United States of America</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Metabolon Inc., Durham, North Carolina, United States of America</addr-line></aff>
<aff id="aff006"><label>6</label> <addr-line>Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America</addr-line></aff>
<aff id="aff007"><label>7</label> <addr-line>Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, Kentucky, United States of America</addr-line></aff>
<aff id="aff008"><label>8</label> <addr-line>F. Joseph Halcomb III, M.D. Department of Biomedical Engineering, University of Kentucky, Lexington, Kentucky, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" ns0:type="simple">
<name name-style="western">
<surname>Reichmann</surname>
<given-names>Florian</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1" />
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Leicester, UNITED KINGDOM</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>Scott McCulloch is employed by Metabolon Inc. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<corresp id="cor001">* E-mail: <email ns0:type="simple">ailing.lin@uky.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>8</issue>
<elocation-id>e0221828</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Hoffman et al</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" ns0:href="info:doi/10.1371/journal.pone.0221828" />
<abstract>
<p>The apolipoprotein <italic>&#949;4</italic> allele (<italic>APOE4</italic>) is the strongest genetic risk factor for Alzheimer&#8217;s disease (AD). <italic>APOE4</italic> carriers develop systemic metabolic dysfunction decades before showing AD symptoms. Accumulating evidence shows that the metabolic dysfunction accelerates AD development, including exacerbated amyloid-beta (A&#946;) retention, neuroinflammation and cognitive decline. Therefore, preserving metabolic function early on may be critical to reducing the risk for AD. Here, we show that inulin increases beneficial microbiota and decreases harmful microbiota in the feces of young, asymptomatic <italic>APOE4</italic> transgenic (E4FAD) mice and enhances metabolism in the cecum, periphery and brain, as demonstrated by increases in the levels of SCFAs, tryptophan-derived metabolites, bile acids, glycolytic metabolites and scyllo-inositol. We show that inulin also reduces inflammatory gene expression in the hippocampus. This knowledge can be utilized to design early precision nutrition intervention strategies that use a prebiotic diet to enhance systemic metabolism and may be useful for reducing AD risk in asymptomatic <italic>APOE4</italic> carriers.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>R01AG054459</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5197-2219</contrib-id>
<name name-style="western">
<surname>Lin</surname>
<given-names>Ai-Ling</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>R01AG062480</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5197-2219</contrib-id>
<name name-style="western">
<surname>Lin</surname>
<given-names>Ai-Ling</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>UL1TR000117</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5197-2219</contrib-id>
<name name-style="western">
<surname>Lin</surname>
<given-names>Ai-Ling</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000049</institution-id>
<institution>National Institute on Aging</institution>
</institution-wrap>
</funding-source>
<award-id>R21AG058006</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Morganti</surname>
<given-names>Josh M.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000062</institution-id>
<institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution>
</institution-wrap>
</funding-source>
<award-id>T32DK007778</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Hoffman</surname>
<given-names>Jared D.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000062</institution-id>
<institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution>
</institution-wrap>
</funding-source>
<award-id>T32Dk007778</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Yanckello</surname>
<given-names>Lucille M.</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000965</institution-id>
<institution>American Federation for Aging Research</institution>
</institution-wrap>
</funding-source>
<award-id>A12474</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5197-2219</contrib-id>
<name name-style="western">
<surname>Lin</surname>
<given-names>Ai-Ling</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This research was supported by NIH grants R01AG054459 (funded by NIA and ODS), R01AG062480, NIH/CTSA grant UL1TR000117, and American Federation for Aging Research Grant #A12474 to A-LL and NIH/NIA R21AG058006 to JMM, and NIH/NIDDK Training Grant T32DK007778 to JDH and LMY. The 7T ClinScan small animal MRI scanner of the UK was funded by the S10 NIH Shared Instrumentation Program Grant (1S10RR029541-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. SDM is employed by Metabolon Inc.. Metabolon Inc. provided support in the form of salary for author SDM but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="7" />
<table-count count="2" />
<page-count count="22" />
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>The microbiome gene amplicon sequence data are available atNCBI BioProject database (PRJNA540508). All other relevant data are within the paper.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Alzheimer&#8217;s disease (AD) is most common form of dementia with hallmarks of amyloid beta (A&#946;) plaques and neurofibrillary tau tangles [<xref ref-type="bibr" rid="pone.0221828.ref001">1</xref>]. Research on AD has long been dominated by communications regarding the A&#946; hypothesis and targeting A&#946; accumulation in the brain through pharmacological therapies. Unfortunately, this research strategy has failed to produce any FDA-approved disease-modifying therapeutics for Alzheimer&#8217;s disease despite over 900 interventional studies completed and registered in the ClinicalTrials.gov database [<xref ref-type="bibr" rid="pone.0221828.ref002">2</xref>]. Accumulating evidence suggests that systemic metabolic dysfunction, oxidative stress and inflammation contribute greatly to AD risk as individuals with insulin resistance, hyperlipidemia, obesity, type 2 diabetes, and other metabolic diseases are at an increased risk for AD [<xref ref-type="bibr" rid="pone.0221828.ref003">3</xref>]. The metabolic deficits and increased inflammation and oxidative stress may occur decades before A&#946; and tau retention become evident [<xref ref-type="bibr" rid="pone.0221828.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0221828.ref005">5</xref>].</p>
<p>The metabolism-induced AD acceleration is specifically true for carriers of the <italic>&#949;4</italic> allelic variant of the <italic>APOE</italic> gene (HGNC:613), the strongest genetic risk factor for late-onset AD [<xref ref-type="bibr" rid="pone.0221828.ref006">6</xref>]. Decades before the aggregation of A&#946;, asymptomatic <italic>APOE4</italic> carriers already show metabolic deficits that may lead to disease progression. Young and middle-aged cognitively normal <italic>APOE4</italic> carriers have reduced glucose uptake in the brain [<xref ref-type="bibr" rid="pone.0221828.ref007">7</xref>]. Similarly, <italic>APOE4</italic> transgenic mice have mitochondrial dysfunction, insulin-signaling impairment, and alterations of the pentose phosphate pathway (PPP) [<xref ref-type="bibr" rid="pone.0221828.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0221828.ref009">9</xref>]. Systemically, <italic>APOE4</italic> carriers have significantly elevated fasting glucose and insulin levels along with an increased risk of metabolic syndrome [<xref ref-type="bibr" rid="pone.0221828.ref010">10</xref>] and chronic low-grade inflammation [<xref ref-type="bibr" rid="pone.0221828.ref011">11</xref>]. Accordingly, it is critical for <italic>APOE4</italic> carriers to reduce their risk of AD by systemically preserving metabolic function and reducing inflammation.</p>
<p>Emerging evidence shows that the gut microbiome plays a critical role in modulating metabolism, immune function, and A&#946; deposition in the host [<xref ref-type="bibr" rid="pone.0221828.ref012">12</xref>&#8211;<xref ref-type="bibr" rid="pone.0221828.ref015">15</xref>], implicating it in the modulation of AD pathology [<xref ref-type="bibr" rid="pone.0221828.ref016">16</xref>]. The three most studied categories of metabolites produced in host-microbiota interactions are short-chain fatty acids (SCFAs), bile acids, and tryptophan-derived metabolites [<xref ref-type="bibr" rid="pone.0221828.ref017">17</xref>]. SCFAs, including butyrate, acetate and propionate, have a dramatic impact on metabolic function [<xref ref-type="bibr" rid="pone.0221828.ref018">18</xref>]. Bile acids significantly impact pathways involved in host cholesterol, lipid and glucose metabolism, and inflammation, and have the potential to alter the host immunity [<xref ref-type="bibr" rid="pone.0221828.ref019">19</xref>] and circadian rhythms [<xref ref-type="bibr" rid="pone.0221828.ref020">20</xref>]. Indole-3-propionic acid, a tryptophan-derived metabolite, can inhibit A&#946; fibril formation in neurons and neuroblastoma cells [<xref ref-type="bibr" rid="pone.0221828.ref021">21</xref>]. On the other hand, A&#946; and lipopolysaccharides can be secreted by some gut microbiota, activating microglia and leading to neuroinflammation [<xref ref-type="bibr" rid="pone.0221828.ref022">22</xref>].</p>
<p>In this study, our goal was to determine whether controlling gut microbial composition and activity via a dietary intervention can protect systemic metabolic functions through the gut-brain axis in asymptomatic <italic>APOE4</italic> mice compared to their <italic>APOE3</italic> littermates. We used a dietary supplement containing Inulin, a non-digestible carbohydrate fiber fermented in the gastrointestinal tract. Inulin is a well-studied prebiotic compound consisting of indigestible fiber that stimulates the growth and activity of SCFA-producing bacteria [<xref ref-type="bibr" rid="pone.0221828.ref023">23</xref>]. In addition, inulin has been demonstrated to increase glucose sensitivity, decrease blood cholesterol and oxidative stress, and prevent neurodegeneration [<xref ref-type="bibr" rid="pone.0221828.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0221828.ref015">15</xref>, <xref ref-type="bibr" rid="pone.0221828.ref024">24</xref>]. We hypothesized that inulin would alter the gut microbiome, enhance systemic metabolism and reduce neuroinflammation in the asymptomatic <italic>APOE4</italic> mice.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Methods</title>
<sec id="sec003" sec-type="materials|methods">
<title>Experimental design</title>
<p>We used a C57BL/6 mouse model which accumulates human A&#946;<sub>42</sub> due to coexpression of 5 familial-AD (5xFAD) mutations in conjunction with human targeted replacement <italic>APOE</italic> (<italic>&#949;4</italic> in the <italic>E4</italic>FAD line and <italic>&#949;3</italic> in the <italic>E3</italic>FAD line) which typically do not develop AD symptoms until 8&#8211;10 months of age [<xref ref-type="bibr" rid="pone.0221828.ref025">25</xref>]. We obtained the breeders from Dr. Mary Jo LaDu of the University of Illinois at Chicago [<xref ref-type="bibr" rid="pone.0221828.ref026">26</xref>], and established our own colony at the University of Kentucky. Each mouse was genotyped to verify their <italic>APOE</italic> and FAD genotype via Transnetyx Inc. (Cordova, TN, USA) after weaning. The experimental diet treatments began when mice were three months of age, before they started to show A&#946; retention or cognitive impairment. We fed <italic>E4</italic>FAD mice either a prebiotic diet containing inulin that is fermentable (<italic>E4</italic>FAD-Inulin) or a control diet containing cellulose that is nonfermentable (<italic>E4</italic>FAD-Control) for a period of 16 weeks [<xref ref-type="bibr" rid="pone.0221828.ref027">27</xref>]. As an additional control, we fed <italic>E3</italic>FAD mice the control diet (<italic>E3</italic>FAD-Control) to compare the results from the <italic>APOE &#949;4</italic> genotype with the more common <italic>APOE &#949;3</italic> genotype, which is considered risk-neutral for AD.</p>
<p><xref ref-type="table" rid="pone.0221828.t001">Table 1</xref> shows the composition of the control and inulin diets. We fed the mice 8% inulin because it has been shown that 8% inulin increased cecal contents, produced more SCFA, and increased the amount of bacterial enzymes in the cecum compared to 4% inulin [<xref ref-type="bibr" rid="pone.0221828.ref028">28</xref>], which is consistent with human studies that 8% fiber (40 g of fiber per day) was considered the maximum tolerable and beneficial quantity to the western human organism [<xref ref-type="bibr" rid="pone.0221828.ref029">29</xref>].</p>
<table-wrap id="pone.0221828.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.t001</object-id>
<label>Table 1</label> <caption><title>Composition of the control and inulin diets.</title></caption>
<alternatives>
<graphic id="pone.0221828.t001g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.t001" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="center">Diet</th>
<th align="center">Prebiotic Diet</th>
<th align="center">Control Diet</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center"><bold>Protein %</bold></td>
<td align="center">18.2</td>
<td align="center">18.2</td>
</tr>
<tr>
<td align="center"><bold>Carbohydrates %</bold></td>
<td align="center">67.8</td>
<td align="center">60.2</td>
</tr>
<tr>
<td align="center"><bold>Fat %</bold></td>
<td align="center">7.1</td>
<td align="center">7.1</td>
</tr>
<tr>
<td align="center"><bold>Fiber %</bold></td>
<td align="center">8.0 (Inulin)</td>
<td align="center">8.0 (Cellulose)</td>
</tr>
<tr>
<td align="center"><bold>Energy (kcal/g)</bold><xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="center">4.08</td>
<td align="center">3.78</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>* Energy (kcal/g)&#8212;Sum of decimal fractions of protein, fat and carbohydrate x 4, 9, and 4 kcal/g, respectively.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The mice had ad libitum access to the diets, and we measured the weight of the remaining food biweekly to estimate the food intake during the 16-week feeding period. The bodyweight was also measured accordingly at the same time.</p>
<p>We determined the sample size (N = 15/group, M:F = 50:50) via power analysis to ensure comparison at a 0.05 level of significance and 90% chance of detecting a true difference of each measured variable between the three groups. Each mouse was housed individually to avoid feces exchange [<xref ref-type="bibr" rid="pone.0221828.ref030">30</xref>]. The mice were weighed biweekly and given <italic>ad libitum</italic> access to food and water. After 16-weeks of feeding (when the mice reached 7 months of age), we collected fecal samples, assessed cognitive functions and measured <italic>in vivo</italic> brain metabolites before sacrificing the mice. Mice were euthanized by CO<sub>2</sub> inhalation and decapitated. Cecum, blood and brain tissues were collected thereafter for metabolomics and other biochemical analyses (e.g., proinflammatory gene expression and A&#946; immunohistochemical staining). All experimental procedures were performed according to NIH guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky (UK).</p>
</sec>
<sec id="sec004">
<title>Behavior assessments</title>
<p>We performed the radial arm water maze (RAWM) task to measure both spatial working memory and spatial reference memory following a 2-day testing paradigm [<xref ref-type="bibr" rid="pone.0221828.ref031">31</xref>]. A staggered training schedule was used, running the mice in cohorts of ten mice, while alternating the different cohorts through the trials over day 1 and day 2 of the test. This alternating protocol was used to avoid the learning limitations imposed by mass sequential trials and to avoid fatigue that may result from consecutive trials. Day 1 is the &#8220;learning&#8221; phase where mice went through three blocks (Blocks 1&#8211;3; 5 trials in each block) to test learning and short-term spatial memory. Day 2 is the &#8220;recall&#8221; phase where mice went through three additional blocks (Blocks 4&#8211;6) to test long-term memory after a 24-hour retention period to locate the platform. It is expected that after the two-day training, the mice with intact memory can find the platform with minimal errors. Geometric extra-maze visual cues were fixed throughout the study on three sides of the curtains. Visual platform trials were included in the training and were used to determine if visual impairment could be a cofounding variable. Mouse performance was recorded by EthoVision XT 8.0 video tracking software (Noldus Information Technology) and data was analyzed by the EthoVision software for the number of incorrect arm entries which are defined as errors. The video was reviewed for each mouse to ensure that the mice did not employ non-spatial strategies, such as chaining, to solve the task.</p>
</sec>
<sec id="sec005">
<title>Proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS)</title>
<p><sup>1</sup>H-MRS was conducted on a 7T ClinScan MR scanner (Siemens, Germany) at the Magnetic Resonance Imaging &amp; Spectroscopy Center of UK. MRS was utilized to measure metabolites in the hippocampus of a subset (n = 8/group) of mice. Mice were anesthetized with 4.0% isoflurane for induction followed by a 1.5% isoflurane and oxygen mixture for maintenance using a facemask. Heart rate (80&#8211;120 bpm), respiration rate, rectal temperature (37&#8201;&#177;&#8201;0.5&#176;C), and water bath temperature (45&#8211;50&#176;C) for body temperature maintenance were monitored throughout the entire scan. The following metabolites were measured: alanine, total choline, glutamate-glutamine complex, myo-inositol, scyllo-inositol, lactate, NAA, phosphocreatine, total creatine, and taurine [<xref ref-type="bibr" rid="pone.0221828.ref032">32</xref>]. The following were used for a water-suppressed spectrum to test for these metabolites: TR = 1500 ms, TE = 135 ms, spectral width = 60 Hz, and average = 400. A voxel (2.0 mm x 5.0 mm x 1.3 mm) is placed over the bilateral hippocampus. Next, a non-water suppressed spectra is performed with 10 averages. Both of these spectra were processed using the LCModel software to find the absolute concentration of the metabolites. To quantify the concentrations of the metabolites, the following equation was utilized: [<italic>m</italic>] = (S<sub>m</sub>/S<sub>water</sub>)[water]C<sub>n</sub>C<sub>av</sub> where [<italic>m</italic>] is the metabolite concentration, S<sub>m</sub> is the metabolite intensity acquired from MRS, S<sub>water</sub> is the water intensity acquired from MRS, [water] is the concentration of water (55.14mM at 310K), C<sub>n</sub> is the correction for the number of equivalent nuclei for each resonance, and C<sub>av</sub> is the correction for the number of averages [<xref ref-type="bibr" rid="pone.0221828.ref031">31</xref>].</p>
</sec>
<sec id="sec006">
<title>Gut microbiome analysis</title>
<sec id="sec007">
<title>Fecal DNA amplification</title>
<p>Fecal samples were collected from all mice (n = 15/group) and frozen at -80&#176;C until further use. A PowerSoil DNA Isolation Kit (MO BIO Laboratories, Inc.) was used for fecal DNA extraction, according to the manufacturer&#8217;s protocol. Genomic DNA was PCR amplified with primers CS1_515F and CS2_926R targeting the V4-V5 regions of microbial 16S rRNA genes using a two-stage &#8220;targeted amplicon sequencing&#8221; protocol [<xref ref-type="bibr" rid="pone.0221828.ref033">33</xref>]. First stage amplifications were performed with the following thermocycling conditions: 95&#176;C for 3 minutes, 28 cycles of 95&#176;C for 45 seconds, 55&#176;C for 45 seconds, 72&#176;C for 90 seconds and final elongation at 72&#176;C for 10 minutes. Barcoding was performed using a second-stage PCR amplification with Access Array Barcode Library for Illumina Sequencers (Fluidigm, South San Francisco, CA; Item# 100&#8211;4876). The pooled libraries, with a 15% phiX spike-in, were loaded on a MiSeq v3 flow cell, and sequenced using an Illumina MiSeq sequencer, with paired-end 300 base reads. Fluidigm sequencing primers, targeting the CS1 and CS2 linker regions, were used to initiate sequencing. De-multiplexing of reads was performed on the instrument. Second stage PCR amplification and library pooling was performed at the University of Illinois at Chicago Sequencing Core. Sequencing was performed at the W.M. Keck Center for Comparative and Functional Genomics at the University of Illinois at Urbana-Champaign. The gene amplicon sequence data generated as part of this study have been submitted to the NCBI BioProject database (PRJNA540508).</p>
</sec>
<sec id="sec008">
<title>Microbial analysis</title>
<p>Forward and reverse reads were merged using PEAR [<xref ref-type="bibr" rid="pone.0221828.ref034">34</xref>]. Primer sequences were identified using Smith-Watermann alignment and trimmed from the sequence. Reads lacking either primer sequence were discarded. Sequences were then trimmed based on quality scores using a modified Mott algorithm with PHRED quality threshold of p = 0.01, and sequences shorter than 300 bases after trimming were discarded. QIIME v1.8 was used to generate OTU tables and taxonomic summaries [<xref ref-type="bibr" rid="pone.0221828.ref035">35</xref>]. Briefly, the resulting sequence files were merged with sample information. Operational taxonomic unit (OTU) clusters were generated in a <italic>de novo</italic> manner using the UCLUST algorithm with a 97% similarity threshold [<xref ref-type="bibr" rid="pone.0221828.ref036">36</xref>]. Chimeric sequences were identified using the USEARCH61 algorithm with the GreenGenes 13_8 reference sequences [<xref ref-type="bibr" rid="pone.0221828.ref037">37</xref>]. Taxonomic annotations for each OTU were using the UCLUST algorithm and GreenGenes 13_8 reference with a minimum similarity threshold of 90% [<xref ref-type="bibr" rid="pone.0221828.ref036">36</xref>, <xref ref-type="bibr" rid="pone.0221828.ref037">37</xref>]. Taxonomic and OTU abundance data were merged into a single OTU table and summaries of absolute abundances of taxa were generated for all phyla, classes, orders, families, genera, and species present in the dataset. The taxonomic summary tables were then rarefied to a depth of 10,000 counts per sample.</p>
<p>Shannon and Bray-Curtis indices were calculated with default parameters in R using the vegan library [<xref ref-type="bibr" rid="pone.0221828.ref038">38</xref>]. The rarefied species data, taxonomic level 7, were used to calculate both indices. Plots were generated in R using the ggplot2 library [<xref ref-type="bibr" rid="pone.0221828.ref039">39</xref>]. Significant difference among tested groups was determined using the Kruskal-Wallis one-way analysis of variance. The group significance tests were performed on the rarefied species data, taxonomic level 6 (genus), using the group_significance.py script within the QIIME v1.8 package.</p>
</sec>
</sec>
<sec id="sec009">
<title>Metabolomic profiling</title>
<p>To determine whether changes in the gut microbial community in inulin-fed <italic>E4</italic>AD mice correlated with changes in systemic metabolism and microbial metabolites, we examined metabolic changes in the gut, periphery, and brain of experimental mice using metabolomics profiling. Metabolomics were performed by Metabolon Inc. (Durham, NC). Metabolon&#8217;s standard solvent extraction method was used to prepare the samples for analysis via liquid chromatography/mass spectrometry (LC/MS) using their standard protocol [<xref ref-type="bibr" rid="pone.0221828.ref040">40</xref>].</p>
<sec id="sec010">
<title>SCFA measurement</title>
<p>For SCFA analysis in the whole blood and cecal contents, eight SCFAs were analyzed by LC-MS/MS. These were as follows: acetic acid (C2), propionic acid (C3), isobutyric acid (C4), 2-methylbutyric acid (C5), isovaleric acid (C5), valeric acid (C5), and caproic acid (C6). Both sets of samples are stable labelled with internal standards and homogenized in an organic solvent. The samples are then centrifuged followed by an aliquot of the supernatant used to derivatize to form SCFA hydrazides. This reaction mixture is subsequently diluted, and an aliquot is injected into an Agilent 1290/AB Sciex QTrap 5500 LCMS/MS system. This system is equipped with a C18 reversed phase UHPLC column operated in negative mode using electrospray ionization [<xref ref-type="bibr" rid="pone.0221828.ref041">41</xref>]. The raw data was analyzed by AB SCIEX software (Analyst 1.6.2) with reduction of the data done in Microsoft Excel 2013. Analysis was done in a 96-well plate with two calibration curves and 6&#8211;8 quality control samples per batch. Samples were labeled BLOQ is they fell below the quantitation limit with ALOQ being labeled for samples above the quantitation limit.</p>
</sec>
<sec id="sec011">
<title>Sample preparation</title>
<p>Each sample was accessioned into a LIMS system, assigned a unique identifier, and stored at -70&#176;C. To remove protein, dissociate small molecules bound to protein or trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, proteins were precipitated with methanol, with vigorous shaking for 2 minutes (Glen Mills Genogrinder 2000) as described previously [<xref ref-type="bibr" rid="pone.0221828.ref042">42</xref>]. The resulting extract was divided into five fractions: two for analysis by ultra-high-performance liquid chromatography-tandem mass spectrometry run in positive mode (UPLC-MS/MS+; early and late; C18 column), two for analysis by UPLC-MS/MS run in negative mode (UPLC-MS/MS-; C18 column and HILIC column), and one aliquot was retained for backup analysis, if needed.</p>
</sec>
<sec id="sec012">
<title>Mass spectrometry analysis</title>
<p>Non-targeted UPLC-MS/MS were performed at Metabolon, Inc. as described [<xref ref-type="bibr" rid="pone.0221828.ref042">42</xref>]. The UPLC/MS/MS portion of the platform incorporates a Waters Acquity UPLC system and a Thermo-Finnegan LTQ mass spectrometer, including an electrospray ionization source and linear ion-trap [<xref ref-type="bibr" rid="pone.0221828.ref043">43</xref>] mass analyzer. Aliquots of the vacuum-dried sample were reconstituted, one each in acidic or basic LC-compatible solvents containing 8 or more injection standards at fixed concentrations (to both ensure injection and chromatographic consistency). Extracts were loaded onto columns (Waters UPLC BEH C18-2.1 x 100 mm, 1.7 &#956;m) and gradient-eluted with water and 95% methanol containing 0.1% formic acid (acidic extracts) or 6.5 mM ammonium bicarbonate (basic extracts). The instrument was set to scan 99&#8211;1000 m/z and alternated between MS and MS/MS scans.</p>
</sec>
<sec id="sec013">
<title>Quality control</title>
<p>All columns and reagents were purchased in bulk from a single lot to complete all related experiments. For monitoring of data quality and process variation, multiple replicates of extracts from a pool of human plasma were prepared in parallel and injected throughout the run, interspersed among the experimental samples. Instrument variability was determined by calculating the median relative standard deviation [<xref ref-type="bibr" rid="pone.0221828.ref027">27</xref>] for the standards that were added to each sample prior to injection into the mass spectrometers (median RSD = 4%; n = 21 standards). Overall process variability was determined by calculating the median RSD for all endogenous metabolites (i.e., non-instrument standards) present in 100% of technical replicate samples created from a homogeneous pool containing a small amount of all study samples (median RSD = 6%; n = 170 metabolites). In addition, process blanks and other quality control samples are spaced evenly among the injections for each day, and all experimental samples are randomly distributed throughout each day&#8217;s run.</p>
</sec>
<sec id="sec014">
<title>Compound identification, quantification, and data curation</title>
<p>Metabolites were identified by automated comparison of the ion features in the experimental samples to a reference library of chemical standard entries that included retention time, molecular weight (m/z), preferred adducts, and in-source fragments as well as associated MS spectra and curated by visual inspection for quality control using software developed at Metabolon [<xref ref-type="bibr" rid="pone.0221828.ref044">44</xref>]. Identification of known chemical entities was based on comparison to metabolomic library entries of more than 2,800 commercially-available purified standards. Subsequent QC and curation processes were utilized to ensure accurate, consistent identification and to minimize system artifacts, mis-assignments, and background noise. Library matches for each compound were verified for each sample. Peaks were quantified using area under the curve. Raw area counts for each metabolite in each sample were normalized to correct for variation resulting from instrument inter-day tuning differences by the median value for each run-day, therefore setting the medians to 1.0 for each run. This preserved variation between samples but allowed metabolites of widely different raw peak areas to be compared on a similar graphical scale. Missing values were imputed with the observed minimum after normalization.</p>
</sec>
<sec id="sec015">
<title>Bioinformatics</title>
<p>The LIMS system encompasses sample accessioning, preparation, instrument analysis and reporting, and advanced data analysis. Additional informatics components include data extraction into a relational database and peak-identification software; proprietary data processing tools for QC and compound identification; and a collection of interpretation and visualization tools for use by data analysts. The hardware and software systems are built on a web-service platform utilizing Microsoft&#8217;s.NET technologies which run on high-performance application servers and fiber-channel storage arrays in clusters to provide active failover and load-balancing.</p>
</sec>
</sec>
<sec id="sec016">
<title>NanoString array</title>
<p>RNA was isolated from the hippocampus using RNeasy Plus kit following manufacturer&#8217;s suggested protocol (Qiagen #74136). Quality and concentration of eluted RNA was measured by Nanodrop spectrophotometer. 200ng of total RNA per sample was quantified using a NanoString array that consisted of 561 gene targets (Mouse Immunology v2 CodeSet). Following quality control, assay background subtraction (geometric mean of negative control values) and housekeeping normalization, there were a total of 318 genes that were examined for all samples. Raw RNA counts were analyzed for differential expression using NanoString&#8217;s analysis software (nSolver 3.0). For the purpose of this experiment we considered only genes that showed at least a 2-fold change biologically relevant, following FDR-adjusted (Bejamini-Hochberg) multiple comparisons correction.</p>
</sec>
<sec id="sec017">
<title>Amyloid-&#946; staining</title>
<p>Mouse brains were collected upon sacrifice and immediately put into a 10% Neutral Buffered Formalin for 24&#8211;48 hours. After this time period, the brains were transferred into 90% ethanol. Next, the brains were sent to the COCVD Pathology Research Core at the University of Kentucky to be embedded and sectioned onto microscope slides for immunohistochemistry. The sectioned tissue undergoes rehydration followed by tissue pretreatment in 90% formic acid for 3 minutes. The tissue was then treated with 3% H<sub>2</sub>O<sub>2</sub> and 10% methanol for 30 minutes. Next, a M.O.M. Kit (Vector Laboratories, Inc. Burlingame, CA) was used following the standard protocol. A&#946; was identified using an anti-A&#946;<sub>1&#8211;17</sub> mouse monoclonal 6E10 antibody (1:3000; Signet Laboratories, Dedham, MA). Following this portion of the protocol, a DAB substrate kit (also Vector Laboratories, Burlingame, CA) was used for visualization. Next, a background stain utilizing NISSL was completed followed by dehydration. The slides were next imaged on the Aperio ScanScope XT Digital Slide Scanner System in the University of Kentucky Alzheimer&#8217;s Disease Center Neuropathology Core Laboratory (20x magnificantion) and uploaded to the online database. Aperio ImageScope (version 12.3.2.8013) was used to analyze total anti-A&#946; counted at 20x magnification (0.495px/um). 10 boxes (ROIs that are 600x600x600 microns) were randomly placed in each sample image and counted for percent positive A&#946; (number of positive + number of strong positive/total number).</p>
</sec>
<sec id="sec018">
<title>Statistical analysis</title>
<p>All statistical analyses were completed using GraphPad Prism (GraphPad, San Diego, CA, USA). Two-tailed Student&#8217;s <italic>t</italic>-test and 1-way ANOVA were performed for determination of differences between groups followed by Tukey&#8217;s multiple comparisons test. Levels of statistical significance were reached when <italic>p</italic> &lt; 0.05. For Metabolon, missing values in the data are assumed to be below the level of detection of the used instruments. Log transformations and imputation of missing values with the minimum observed values for each metabolite was conducted. This was followed by the usage of ANOVA to identify biochemicals that were significantly different between groups. Given the multiple comparisons inherent in analysis of metabolites, between-group relative differences are assessed using both p-value and false discovery rate analysis (q-value).</p>
</sec>
</sec>
<sec id="sec019" sec-type="results">
<title>Results</title>
<sec id="sec020">
<title>Food intake, body weight, cognition and A&#946; retention in <italic>E4</italic>FAD mice</title>
<p>After 16 weeks of feeding (when the mice reached 7 months of age), we found that <italic>E4</italic>FAD-inulin mice had significantly higher food intake than <italic>E4</italic>FAD-Control mice (<xref ref-type="fig" rid="pone.0221828.g001">Fig 1A</xref>), but did not show any difference in bodyweight compared to <italic>E4</italic>FAD and <italic>E3</italic>FAD controls (<xref ref-type="fig" rid="pone.0221828.g001">Fig 1B</xref>). We assessed learning ability, spatial working and reference memory using RAWM behavioral tests, and did not find significant differences among the three groups during either the learning phase (Day 1, blocks 1&#8211;3) or the memory recall phase (Day 2, blocks 4&#8211;6; <xref ref-type="fig" rid="pone.0221828.g001">Fig 1C</xref>). Similarly, we did not find a significant difference in A&#946; plaque aggregation among the three groups (<xref ref-type="fig" rid="pone.0221828.g001">Fig 1D</xref>). Our findings are consistent with published reports that <italic>E4</italic>FAD mice can be asymptomatic for AD up to 7 months of age [<xref ref-type="bibr" rid="pone.0221828.ref026">26</xref>].</p>
<fig id="pone.0221828.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Effect of inulin on food intake, body weight, cognition and A&#946; retention in <italic>E4</italic>FAD mice.</title>
<p>Inulin intake increased daily energy uptake (kcal/d) from the diet in the <italic>E4</italic>FAD mice (A) but did not change bodyweight (B). (C) The mice showed no performance differences on the RAWM test. Wrong entries were recorded as errors. There were no significant differences in performance among <italic>E3</italic>FAD-Control, <italic>E4</italic>FAD-Control and <italic>E4</italic>FAD-Inulin mice in any of the 6 blocks. (D) Representative images of A&#946; immunohistochemical staining from the three groups of mice (Top) and quantitation of the A&#946; load (Bottom). There were no significant differences in A&#946; load among the three groups of mice. Data are presented as the mean &#177; SEM. n.s. = not significant; *<italic>p</italic> &lt; 0.05.</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.g001" ns0:type="simple" />
</fig>
</sec>
<sec id="sec021">
<title>Inulin alters gut microbiome diversity in <italic>E4</italic>FAD mice</title>
<p>Interestingly, we found that the prebiotic inulin diet significantly altered gut microbiome diversity in <italic>E4</italic>FAD mice. Based on evaluation of the alpha (&#945;) diversity metric (<italic>i</italic>.<italic>e</italic>., Shannon index, H) of the fecal microbial community, <italic>E4</italic>FAD-Inulin mice had significantly lower diversity (at the genus level) than <italic>E4</italic>FAD-Control mice (Gaussian link function, p = 0.019; <xref ref-type="fig" rid="pone.0221828.g002">Fig 2A</xref>). By employing the Bray-Curtis dissimilarity metric followed by visualization of the data with an ordination plot, we observed that the fecal microbial community structures of <italic>E4</italic>FAD-Inulin mice were significantly different from that of the <italic>E4</italic>FAD-Control mice (ANOSIM R statistic = 0.877; p = 0.001; <xref ref-type="fig" rid="pone.0221828.g002">Fig 2B</xref>). Significant differences in fecal microbial community structure were also observed between <italic>E3</italic>FAD-Control and <italic>E4</italic>FAD-Control mice (ANOSIM R statistic = 0.017; p = 0.013, <xref ref-type="fig" rid="pone.0221828.g002">Fig 2C</xref>), but no significant difference was observed between the fecal microbial communities of FAD(-) and FAD(+) mice (p = ANOSIM R statistic = -0.011; p = 0.546, <xref ref-type="fig" rid="pone.0221828.g002">Fig 2D</xref>) or between <italic>E4</italic>FAD males and females across the two diets (ANOSIM R statistic = 0.066; p = 0.07, <xref ref-type="fig" rid="pone.0221828.g002">Fig 2E</xref>).</p>
<fig id="pone.0221828.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Analysis of inulin-induced changes in gut microbiome diversity.</title>
<p>All analyses were performed on annotated sequence data at the genus level, rarefied to 10,000 sequences per sample. (A) <italic>E4</italic>FAD-Inulin mice had significantly lower &#945;-diversity (shown here as the Shannon index) than <italic>E4</italic>FAD-Control mice (<italic>p</italic> = 0.019). (B) <italic>E4</italic>FAD-Control and <italic>E4</italic>FAD-Inulin mice exhibited a significant difference in &#946;-diversity (p = 0.001). (C) <italic>E3</italic>FAD-Control and <italic>E4</italic>FAD-Control mice exhibited a significant difference in &#946;-diversity (p = 0.013). (D) Mice with and without FAD mutations (FAD (+) vs. FAD(-)) exhibited no significant difference in &#946;-diversity (p = 0.546). (E) Male and female mice did not exhibit a significant difference in &#946;-diversity (p = 0.07).</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.g002" ns0:type="simple" />
</fig>
<p>We further determined the fecal microbial taxa that were differentially abundant in inulin-fed versus control <italic>E4</italic>FAD mice (<xref ref-type="table" rid="pone.0221828.t002">Table 2</xref>). Compared to <italic>E4</italic>FAD-Control mice, the relative abundance of bacteria from the genera <italic>Prevotella</italic> and <italic>Lactobacillus</italic> was elevated in <italic>E4</italic>FAD-Inulin mice, while the relative abundance of <italic>Escherichia</italic>, <italic>Turicibacter</italic> and <italic>Akkermansia</italic> was reduced in <italic>E4</italic>FAD-Inulin mice. <italic>Prevotella spp</italic>. are known to be involved in SCFA production and bile acid metabolism, and their relative abundance has been associated with improved glucose metabolism [<xref ref-type="bibr" rid="pone.0221828.ref045">45</xref>]. <italic>Lactobacillus spp</italic>. are commonly used as a probiotic [<xref ref-type="bibr" rid="pone.0221828.ref046">46</xref>]. Conversely, <italic>Escherichia</italic> and <italic>Turicibacter spp</italic>. have been associated with gastrointestinal (GI) inflammation, metabolic syndrome and diet-induced obesity [<xref ref-type="bibr" rid="pone.0221828.ref047">47</xref>]. Decreased abundance of <italic>Akkermansia spp</italic>. has recently been correlated with high dietary fiber intake and slower degradation of the colonic mucus barrier, thereby protecting against pathogens [<xref ref-type="bibr" rid="pone.0221828.ref048">48</xref>]. Thus, our results reveal that, overall, inulin increased the relative abundance of putatively beneficial gut microbiota and reduced that of putatively proinflammatory taxa within the context of reduced overall &#945;-diversity.</p>
<table-wrap id="pone.0221828.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.t002</object-id>
<label>Table 2</label> <caption><title>Bacterial taxonomic analysis of inulin-induced changes in the gut microbiota of <italic>E4</italic>FAD mice.</title></caption>
<alternatives>
<graphic id="pone.0221828.t002g" mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.t002" ns0:type="simple" />
<table>
<colgroup>
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
<col align="left" valign="middle" />
</colgroup>
<thead>
<tr>
<th align="center" rowspan="3">OTU</th>
<th align="center"><italic>E4</italic> Inulin vs.</th>
<th align="center"><italic>E4</italic> control vs.</th>
<th align="center" rowspan="3">Potential Function/Association</th>
<th align="center" rowspan="3">Citations</th>
</tr>
<tr>
<th align="center"><italic>E4</italic> control</th>
<th align="center"><italic>E3</italic> control</th>
</tr>
<tr>
<th align="center">FDRC (Fold Change)</th>
<th align="center">FDRC (Fold Change)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>k__Bacteria;</bold></td>
<td align="center" rowspan="6">2.17E-03(+1.78)</td>
<td align="center" rowspan="6">_</td>
<td align="center">Involved in bile acid metabolism;</td>
<td align="center" rowspan="6">[<xref ref-type="bibr" rid="pone.0221828.ref049">49</xref>]</td>
</tr>
<tr>
<td align="left"><bold>p__Bacteroidetes;</bold></td>
<td align="center">Has a negative correlation with</td>
</tr>
<tr>
<td align="left"><bold>c__Bacteroidia;</bold></td>
<td align="center">BMI; Involved in SCFA production;</td>
</tr>
<tr>
<td align="left"><bold>o__Bacteroidales;</bold></td>
<td align="center">Increased by a high fiber diet;</td>
</tr>
<tr>
<td align="left"><bold>f__Paraprevotellaceae;</bold></td>
<td align="center">Exerts a protective effect against</td>
</tr>
<tr>
<td align="left"><bold>g__<italic>Prevotella</italic></bold></td>
<td align="center">diabetes</td>
</tr>
<tr>
<td align="left"><bold>k__Bacteria;</bold></td>
<td align="center" rowspan="6">0.02 (+1.48)</td>
<td align="center" rowspan="6">_</td>
<td align="center" />
<td align="center" rowspan="6">[<xref ref-type="bibr" rid="pone.0221828.ref046">46</xref>]</td>
</tr>
<tr>
<td align="left"><bold>p__Firmicutes;</bold></td>
<td align="left" />
</tr>
<tr>
<td align="left"><bold>c__Bacilli;</bold></td>
<td align="center">Common probiotic; Inhibits</td>
</tr>
<tr>
<td align="left"><bold>o__Lactobacillales;</bold></td>
<td align="center">pathogens; produces lactate</td>
</tr>
<tr>
<td align="left"><bold>f__Lactobacillaceae;</bold></td>
<td align="left" />
</tr>
<tr>
<td align="left"><bold>g__<italic>Lactobacillus</italic></bold></td>
<td align="left">&#160;</td>
</tr>
<tr>
<td align="left"><bold>k__Bacteria;</bold></td>
<td align="center" rowspan="6">8.76E-04 (-3.28)</td>
<td align="center" rowspan="6">_</td>
<td align="left">&#160;</td>
<td align="center" rowspan="6">[<xref ref-type="bibr" rid="pone.0221828.ref047">47</xref>]</td>
</tr>
<tr>
<td align="left"><bold>p__Proteobacteria;</bold></td>
<td align="left" />
</tr>
<tr>
<td align="left"><bold>c__Gammaproteobacteria;</bold></td>
<td align="center">Involved in GI disorders and</td>
</tr>
<tr>
<td align="left"><bold>o__Enterobacteriales;</bold></td>
<td align="center">inflammation</td>
</tr>
<tr>
<td align="left"><bold>f__Enterobacteriaceae;</bold></td>
<td align="left">&#160;</td>
</tr>
<tr>
<td align="left"><bold>g__<italic>Escherichia</italic></bold></td>
<td align="left">&#160;</td>
</tr>
<tr>
<td align="left"><bold>k__Bacteria;</bold></td>
<td align="center" rowspan="6">0.03 (-0.47)</td>
<td align="center" rowspan="6">_</td>
<td align="center" />
<td align="center" rowspan="6">[<xref ref-type="bibr" rid="pone.0221828.ref050">50</xref>]</td>
</tr>
<tr>
<td align="left"><bold>p__Firmicutes;</bold></td>
<td align="center">Implicated to have a role in</td>
</tr>
<tr>
<td align="left"><bold>c__Bacilli;</bold></td>
<td align="center">metabolic syndrome; may play a</td>
</tr>
<tr>
<td align="left"><bold>o__Turicibacterales;</bold></td>
<td align="center">role in abnormal metabolism</td>
</tr>
<tr>
<td align="left"><bold>f__Turicibacteraceae;</bold></td>
<td align="center">in Type 2 Diabetes</td>
</tr>
<tr>
<td align="left"><bold>g__<italic>Turicibacter</italic></bold></td>
<td align="left">&#160;</td>
</tr>
<tr>
<td align="left"><bold>k__Bacteria;</bold></td>
<td align="center" rowspan="6">0.02 (-4.54)</td>
<td align="center" rowspan="6">0.01 (7.64)</td>
<td align="center">Strong association with Chron's</td>
<td align="center" rowspan="6">[<xref ref-type="bibr" rid="pone.0221828.ref051">51</xref>]</td>
</tr>
<tr>
<td align="left"><bold>p__Proteobacteria;</bold></td>
<td align="center">disease; Possess many virulence</td>
</tr>
<tr>
<td align="left"><bold>c__Gammaproteobacteria;</bold></td>
<td align="center">factors relevant to GI disease (motility,</td>
</tr>
<tr>
<td align="left"><bold>o__Enterobacteriales;</bold></td>
<td align="center">adherence, urase production, IgA</td>
</tr>
<tr>
<td align="left"><bold>f__Enterobacteriaceae;</bold></td>
<td align="center">proteases, antibiotic resistance); Has</td>
</tr>
<tr>
<td align="left"><bold>g__<italic>Proteus</italic></bold></td>
<td align="center">also been linked to gastroenteritis</td>
</tr>
<tr>
<td align="left"><bold>k__Bacteria;</bold></td>
<td align="center" rowspan="6">1.82E-04 (-0.97)</td>
<td align="center" rowspan="6">-</td>
<td align="center" />
<td align="center" rowspan="6">[<xref ref-type="bibr" rid="pone.0221828.ref048">48</xref>]</td>
</tr>
<tr>
<td align="left"><bold>p__Verrucomicrobia;</bold></td>
<td align="center">Mucin degraders;</td>
</tr>
<tr>
<td align="left"><bold>c__Verrucomicrobiae;</bold></td>
<td align="center">shown to decrease on a high-fiber</td>
</tr>
<tr>
<td align="left"><bold>o__Verrucomicrobiales;</bold></td>
<td align="center">diet, thereby protecting the mucus</td>
</tr>
<tr>
<td align="left"><bold>f__Verrucomicrobiaceae;</bold></td>
<td align="center">layer and intestinal barrier</td>
</tr>
<tr>
<td align="left"><bold>g__<italic>Akkermansia</italic></bold></td>
<td align="center">&#160;</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>The FDRC is the Benjamini-Hochberg false-discovery rate (FDR)-adjusted <italic>p</italic>-value. Only those genus-level taxa with an FDRC &lt;0.05 are shown.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec022">
<title>Inulin enhances systemic metabolism in <italic>E4</italic>FAD mice</title>
<sec id="sec023">
<title>Gut (cecum)</title>
<p>SCFA measurement in the cecum by metabolomic analysis revealed significant increases in cecal acetate (<xref ref-type="fig" rid="pone.0221828.g003">Fig 3A</xref>), butyrate (<xref ref-type="fig" rid="pone.0221828.g003">Fig 3B</xref>), and propionate (<xref ref-type="fig" rid="pone.0221828.g003">Fig 3C</xref>) in <italic>E4</italic>FAD-Inulin mice compared to <italic>E4</italic>FAD-Control mice. These results suggest that dietary supplementation with inulin causes increased fermentation in the cecum that leads to increased production of SCFAs. Additionally, when the cecum was excised at the end of the study, we observed that <italic>E4</italic>FAD-Inulin mice had significantly enlarged ceca compared to the controls (<xref ref-type="fig" rid="pone.0221828.g003">Fig 3D and 3E</xref>). This is likely due to the cecum being the primary site of inulin fermentation [<xref ref-type="bibr" rid="pone.0221828.ref052">52</xref>]. Enlargement of the cecum has been suggested to be a result of increased microbial content [<xref ref-type="bibr" rid="pone.0221828.ref053">53</xref>], which is consistent with our findings.</p>
<fig id="pone.0221828.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Analysis of inulin-induced changes in metabolism and weight in the cecum.</title>
<p><italic>E4</italic>FAD-Inulin fed mice had significantly enhanced production of the short-chain fatty acids (A) acetate; (B) butyrate; and (C) propionate compared to the controls. <italic>E3</italic>FAD-Control and <italic>E4</italic>FAD-Control mice did not exhibit significant differences in these measures. (D) Representative images showing the significantly increased cecum size of the inulin-fed <italic>E4</italic>FAD mice compared to the <italic>E4</italic>FAD control mice. (E) Quantitation of data in (D) comparing the cecum weights among the three groups. Data are presented as the mean &#177; SEM. n.s. = not significant; *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01; ***<italic>p</italic> &lt; 0.001; ****<italic>p</italic> &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.g003" ns0:type="simple" />
</fig>
</sec>
<sec id="sec024">
<title>Periphery (blood)</title>
<p>We next examined whether microbiota-related metabolites were released from the gut to the bloodstream. Since SCFAs, tryptophan metabolites, and bile acids are the three most studied categories of metabolites in host-microbiota interactions [<xref ref-type="bibr" rid="pone.0221828.ref054">54</xref>], we chose to measure these metabolites in mice peripheral blood. We found that acetate was significantly increased in blood in <italic>E4</italic>FAD-Inulin mice compared to <italic>E4</italic>FAD-control mice (<xref ref-type="fig" rid="pone.0221828.g004">Fig 4A</xref>). Although butyrate (<xref ref-type="fig" rid="pone.0221828.g004">Fig 4B</xref>) and propionate (<xref ref-type="fig" rid="pone.0221828.g004">Fig 4C</xref>) were also increased in the bloodstream of <italic>E4</italic>FAD-Inulin mice, the increase was not as substantial as in the cecum. Metabolites related to tryptophan metabolism, including indolepropionate (IPA) (<xref ref-type="fig" rid="pone.0221828.g004">Fig 4D</xref>) and indoleacrylate (<xref ref-type="fig" rid="pone.0221828.g004">Fig 4E</xref>), were observed at much higher levels in <italic>E4</italic>FAD-Inulin mice than in <italic>E4</italic>FAD-Control or <italic>E3</italic>FAD-Control mice. <italic>E4</italic>FAD-Inulin mice also had significantly elevated levels of bile acids, including cholate (<xref ref-type="fig" rid="pone.0221828.g004">Fig 4F</xref>) and deoxycholate (<xref ref-type="fig" rid="pone.0221828.g004">Fig 4G</xref>), compared to <italic>E4</italic>FAD-Control mice.</p>
<fig id="pone.0221828.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Analysis of inulin-induced changes in microbial metabolism changes in the periphery.</title>
<p><italic>E4</italic>FAD-Inulin mice had a significant increase in (A) acetate and trend-level increases in (B) butyrate and (C) propionate. <italic>E4</italic>FAD-Inulin mice had increased tryptophan metabolism, as indicated by the levels of (D) indolepropionate (IPA) and (E) indoleacrylate, and increased bile acid metabolism, as indicated by the levels of (F) cholate and (G) deoxycholate. n.s. = not significant; **<italic>p</italic> &lt; 0.01; ***<italic>p</italic> &lt; 0.001; ****<italic>p</italic> &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.g004" ns0:type="simple" />
</fig>
<p>In addition to microbial metabolites, we found that inulin enhanced the levels of metabolites involved in the mitochondrial tricarboxylic acid (TCA) cycle (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5A</xref>). Succinate (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5B</xref>), fumarate (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5C</xref>), and malate (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5D</xref>) were significantly increased in <italic>E4</italic>FAD-Inulin mice compared to <italic>E3</italic>FAD-Control mice. In contrast, <italic>E4</italic>FAD-Control mice exhibited decreased levels of these metabolites in comparison to <italic>E3</italic>FAD-Control mice, consistent with published reports that <italic>APOE4</italic> carriers had early-onset mitochondrial dysfunction compared to noncarriers [<xref ref-type="bibr" rid="pone.0221828.ref008">8</xref>]. In addition to entering the TCA cycle, glucose in the brain can be metabolized via the PPP to generate NADPH&#8212;the major reducing equivalent in the cell that supports glutathione- and thioredoxin-dependent antioxidant systems [<xref ref-type="bibr" rid="pone.0221828.ref055">55</xref>] (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5A</xref>). In line with this, we found that inulin also enhanced the levels of metabolites generated via the PPP, including ribose (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5E</xref>), ribulose (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5F</xref>), ribonate (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5G</xref>), and arabonate (<xref ref-type="fig" rid="pone.0221828.g005">Fig 5H</xref>), suggesting that dietary supplementation with inulin may reduce cellular oxidative stress and enhance antioxidant function.</p>
<fig id="pone.0221828.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Analysis of inulin-induced changes in glycolytic metabolism in the periphery.</title>
<p>(A) An illustration of the glycolytic pathway through the TCA cycle and PPP. <italic>E4</italic>FAD mice fed prebiotic inulin showed changes in the levels of TCA cycle metabolites, including (B) succinate, (C) fumarate, and (D) malate, compared to <italic>E4</italic>FAD mice fed the control diet. <italic>E4</italic>FAD mice fed the prebiotic inulin showed a significant increase in the levels PPP-associated metabolites including (E) ribose, (F) ribulose, (G) ribonate, and (H) arabonate compared to <italic>E4</italic>FAD mice fed the control diet. n.s. = not significant; *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01.</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.g005" ns0:type="simple" />
</fig>
</sec>
<sec id="sec025">
<title>Brain (hippocampus)</title>
<p>Using <italic>in vivo</italic> <sup>1</sup>H-MRS to acquire spectra from the hippocampal voxel of experimental mice (<xref ref-type="fig" rid="pone.0221828.g006">Fig 6A</xref>), we found that the levels of scyllo-inositol, a microbiota-produced metabolite, was increased in the hippocampus of <italic>E4</italic>FAD-Inulin mice, compared to control mice (<xref ref-type="fig" rid="pone.0221828.g006">Fig 6B and 6C</xref>). The results indicate that the scyllo-inositol produced by the gut microbiome in response to dietary inulin can reach the hippocampus. We also observed that the increase in scyllo-inositol was accompanied by a decrease in myo-inositol (<xref ref-type="fig" rid="pone.0221828.g006">Fig 6D</xref>). Scyllo-inositol is a microbiota-produced metabolite and has been used to inhibit A&#946; aggregation in clinical trials [<xref ref-type="bibr" rid="pone.0221828.ref056">56</xref>], while myo-inositol has been shown to be increased in <italic>APOE4</italic> carriers with preclinical AD before detection of elevated A&#946; levels [<xref ref-type="bibr" rid="pone.0221828.ref057">57</xref>]. Administration of scyllo-inositol has been shown to lead to a reduction in elevated brain myo-inositol levels in AD [<xref ref-type="bibr" rid="pone.0221828.ref058">58</xref>].</p>
<fig id="pone.0221828.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Analysis of inulin-induced changes in microbial metabolism in the brain.</title>
<p>Scyllo-inositol was dramatically increased in the hippocampus of <italic>E4</italic>FAD mice fed the prebiotic inulin compared to the <italic>E4</italic>FAD mice fed the control diet. (A) Shows the voxel that was used for MRS. Representative spectra are shown for (B) the <italic>E3</italic>FAD-Control, <italic>E4</italic>FAD-Control, and <italic>E4</italic>FAD-Inulin groups. The arrow indicates scyllo-inositol, which was dramatically increased in mice fed the prebiotic inulin. Scyllo-inositol (C) was significantly increased in E4FAD inulin mice compared to control fed E3FAD and E4FAD mice. Myo-inositol (D) was significantly decreased in E4FAD mice fed inulin. Data are the mean &#177; SEM, n.s. = not significant; ****<italic>p</italic> &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.g006" ns0:type="simple" />
</fig>
</sec>
</sec>
<sec id="sec026">
<title>Inulin decreases brain inflammation in <italic>E4</italic>FAD mice</title>
<p>Since Familial Alzheimer&#8217;s disease (FAD) mutations result in increased production of A&#946; leading to neuroinflammation [<xref ref-type="bibr" rid="pone.0221828.ref059">59</xref>], we decided to examine whether dietary inulin impacts inflammatory gene expression in the hippocampus of <italic>APOE4</italic> mice with FAD mutations. We found that among 318 genes, 52 were enriched in <italic>APOE4</italic> mice with FAD mutations (<xref ref-type="fig" rid="pone.0221828.g007">Fig 7A</xref>). This suggests that the FAD mutations do indeed significantly enhance neuroinflammation in the hippocampus of the <italic>E4</italic>FAD mice. Among the 52 enriched genes, the greatest change in expression was observed in 4 genes that had a 2-fold lower level of expression in <italic>E4</italic>FAD-Inulin mice compared to <italic>E4</italic>FAD-Control mice (<xref ref-type="fig" rid="pone.0221828.g007">Fig 7B</xref>). Two of these genes that were significantly decreased in expression were chemokine (C-C motif) ligand 4 (<italic>CCL4</italic>; MGI:98261) (<xref ref-type="fig" rid="pone.0221828.g007">Fig 7C</xref>) and Fc receptor IgG low affinity 4 (<italic>Fcgr4</italic>; MGI:2179523) (<xref ref-type="fig" rid="pone.0221828.g007">Fig 7D</xref>). C-X-C motif chemokine 10 (<italic>CXCL10</italic>; MGI:1352450) (<xref ref-type="fig" rid="pone.0221828.g007">Fig 7E</xref>) and integrin alpha X (<italic>Itgax</italic>; MGI:96609) (<xref ref-type="fig" rid="pone.0221828.g007">Fig 7F</xref>) had a trend toward significant. Notably, these four proinflammatory genes were minimally expressed in <italic>APOE4</italic> mice without FAD mutations, implying their importance in AD. Along with this, differences in diet did not show any significant effects (<xref ref-type="fig" rid="pone.0221828.g007">Fig 7C&#8211;7F</xref>).</p>
<fig id="pone.0221828.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0221828.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Analysis of inulin-induced changes in inflammatory gene expression in the hippocampus.</title>
<p>(A) In <italic>APOE4</italic> mice with and without the FAD mutations, data are plotted as the mean expression ratios with their respective FDR-adjusted <italic>p</italic>-value. This revealed 52 genes that were significantly differentially enriched (magenta) with log<sub>2</sub> (fold change) greater than one due to the FAD mutations. (B) The 52 genes that were enriched due to the FAD mutations were further examined in the context of diet manipulation. Overall, there was a trend for most of the 52 genes to be downregulated due to the prebiotic inulin in <italic>E4</italic>FAD mice (e.g., gray bars). Furthermore, an approximately 2-fold decrease in expression was observed in 4 genes (aquamarine). Among these, (C) <italic>CCL4</italic>, and (D) <italic>Fcgr4</italic> were significantly decreased. Although there was a strong visual trend for both (E) <italic>CXCL10</italic> and (F) <italic>Itgax</italic> to be decreased due to the prebiotic inulin, these decreases were not statistically significant. Data are mean &#177; SEM, n.s. = not significant; *<italic>p</italic> &lt; 0.05.</p>
</caption>
<graphic mimetype="image" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.g007" ns0:type="simple" />
</fig>
</sec>
</sec>
<sec id="sec027" sec-type="conclusions">
<title>Discussion</title>
<p><italic>APOE4</italic> carriers may develop systemic metabolic dysfunction decades before the onset of Alzheimer&#8217;s disease. Early interventions to protect and preserve metabolic functions in asymptomatic <italic>APOE4</italic> carriers are critical to reduce or eliminate the risk of AD. In this study, we demonstrate that a diet supplemented with the prebiotic inulin leads to an altered gut microbiome, increased microbial metabolism via gut-brain axis components, enhanced glycolytic metabolism in the periphery, and reduced hippocampal inflammatory gene expression in asymptomatic <italic>E4</italic>FAD mice. The findings are consistent with literature, showing that targeting the gut microbiome with inulin can modulate the peripheral immune response and alter neuroinflammation in middle age mice [<xref ref-type="bibr" rid="pone.0221828.ref060">60</xref>], and reduce oxidative stress and prevent neurodegeneration as well as atherosclerosis in mice fed with high-fat diet [<xref ref-type="bibr" rid="pone.0221828.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0221828.ref015">15</xref>].</p>
<p>Our analyses of the gut microbiome revealed that mice fed an inulin-supplemented diet display increased abundance of <italic>Prevotella</italic> and <italic>Lactobacillus spp</italic>. Consistent with reports that <italic>Prevotella spp</italic>. are involved in the production of SCFAs, bile acids, and succinate [<xref ref-type="bibr" rid="pone.0221828.ref049">49</xref>], we observed an elevation of SCFAs in the cecum and the blood, and an elevation of bile acids and succinate in the blood of inulin- fed mice. SCFAs play a major role in modulating glucose homeostasis. In particular, butyrate has been shown to improve mitochondrial function, increase glucose sensitivity and decrease inflammation; acetate has been shown to decrease appetite and body fat and to increase mitochondrial efficiency; and propionate has been shown to increase glucose sensitivity, regulate body weight and modulate lipid metabolism [<xref ref-type="bibr" rid="pone.0221828.ref061">61</xref>]. Bile acids regulate lipid, glucose and energy homeostasis as well as their own synthesis, detoxification and transport [<xref ref-type="bibr" rid="pone.0221828.ref062">62</xref>]. Changes in SCFA and bile acid levels in inulin-fed <italic>E4</italic>AD mice suggest improved glucose metabolism and mitochondrial function. We found increased metabolites related to glycolytic metabolism, including components of the mitochondrial TCA cycle, such as succinate, as well as components of the PPP. As the PPP is a major antioxidant system, increases in <italic>Prevotella</italic> may indicate an enhancement of immune function. Similarly, increases in the relative abundance of <italic>Lactobacillus</italic> may also relate to improved immune function. <italic>Lactobacillus spp</italic>. are commonly used as probiotics to improve digestion and boost immunity, and can also help inhibit the growth of harmful bacteria and improve intestinal flora balance [<xref ref-type="bibr" rid="pone.0221828.ref063">63</xref>]. This is consistent with our findings that the relative abundance of several potentially harmful microbial taxa was decreased in <italic>E4</italic>FAD-Inulin mice relative to <italic>E4</italic>FAD-Control mice, including <italic>Escherichia</italic>, and <italic>Turicibacter</italic> and <italic>Proteus</italic>. While the relative abundance of <italic>Proteus</italic> was substantially higher in <italic>E4</italic>FAD-Control mice than in <italic>E3</italic>FAD-Control animals, this abundance was significantly reduced in <italic>E4</italic>FAD-Inulin mice. The relative abundance of <italic>Akkermansia spp</italic> that has been shown to have both positive and negative effects on host health, was also decreased in <italic>E4</italic>FAD-Inulin relative to <italic>E4</italic>FAD-Control mice. In a recent study of a low-fiber diet, <italic>Akkermansia spp</italic>. were shown to increase in abundance and express mucin-degrading enzymes [<xref ref-type="bibr" rid="pone.0221828.ref048">48</xref>]. Mucin degradation that leads to gut barrier degradation and increased susceptibility to pathogens, was mitigated by a high-fiber diet [<xref ref-type="bibr" rid="pone.0221828.ref048">48</xref>]. The reduced relative abundance of <italic>Akkermansia</italic> in <italic>E4</italic>FAD-Inulin mice relative to <italic>E4</italic>FAD-Control mice could indicate a protective role of fiber through both a decrease in the abundance and activity of mucin-degrading species and a decrease in the general production of SCFAs, leading to increased gut barrier integrity. Collectively, our findings of inulin-induced alterations in the gut microbiome demonstrate potential enhancements in systemic metabolic and immune functions.</p>
<p>We show that &#945;-diversity is lower in the <italic>E4</italic>FAD-Inulin mice than in the <italic>E4</italic>FAD-Control mice. Although an increase in &#945;-diversity has been reported to be beneficial in obesity and type 2 diabetes mellitus (T2DM) [<xref ref-type="bibr" rid="pone.0221828.ref064">64</xref>], our group and others have found the opposite to be true in mouse models for AD [<xref ref-type="bibr" rid="pone.0221828.ref065">65</xref>&#8211;<xref ref-type="bibr" rid="pone.0221828.ref067">67</xref>]. We reported that aging-induced dysbiosis (gut microbiome imbalance) increases &#945;-diversity in aged mice [<xref ref-type="bibr" rid="pone.0221828.ref065">65</xref>] while mice fed a ketogenic diet had reduced &#945;-diversity with increased beneficial microbiota [<xref ref-type="bibr" rid="pone.0221828.ref066">66</xref>]. Similarly, our current study indicates that dietary supplementation with inulin increases the relative abundance of putatively beneficial gut microbiota and reduces that of putatively proinflammatory taxa in the context of reduced overall &#945;-diversity.</p>
<p>We report a significant increase in scyllo-inositol and decrease in myo-inositol in the hippocampus of the <italic>E4</italic>FAD-Inulin mice. Scyllo-inositol has been reported to be produced by <italic>Bacillus subtilis</italic> [<xref ref-type="bibr" rid="pone.0221828.ref068">68</xref>] and has been used to inhibit A&#946; aggregation in clinical trials [<xref ref-type="bibr" rid="pone.0221828.ref056">56</xref>]. In contrast, myo-inositol is considered an inflammatory marker, and a dramatic increase in myo-inositol suggests increased demyelination and proliferation of glial cells in inflammation [<xref ref-type="bibr" rid="pone.0221828.ref069">69</xref>]. Our findings indicate that dietary inulin can improve immune function and reduce A&#946; aggregation. This is consistent with reduced proinflammatory gene expression in the hippocampus of <italic>E4</italic>FAD-Inulin mice with FAD mutations. We report significant decreases in <italic>CCL4</italic> and <italic>Fcgr4</italic> and a decreased trend for <italic>CXCL10</italic> and <italic>Itgax</italic>. <italic>CCL4</italic> is a chemokine that has been found to be altered in human <italic>APOE4</italic> carriers and is associated with the accumulation of A&#946; in the brain [<xref ref-type="bibr" rid="pone.0221828.ref070">70</xref>]. <italic>Fcgr4</italic>, along with other member of the <italic>FCGR</italic> family, is upregulated under inflammatory conditions and potentially stimulates vascular damage and neurodegeneration [<xref ref-type="bibr" rid="pone.0221828.ref071">71</xref>]. <italic>CXCL10</italic> is a chemokine found in high concentrations in AD, and cerebrospinal fluid <italic>CXCL10</italic> concentrations have been positively correlated with cognitive impairment [<xref ref-type="bibr" rid="pone.0221828.ref072">72</xref>]. Finally, <italic>Itgax</italic> is an inflammatory integrin protein that appears to be induced in degenerative &#8216;MGnD&#8217; microglia in AD [<xref ref-type="bibr" rid="pone.0221828.ref043">43</xref>]. These gene expression data are consistent with <italic>in vivo</italic> brain metabolism data, which show increased scyllo-inositol (A&#946; inhibition) and reduced myo-inositol (decreased inflammation). Taken together, our results show that an inulin-enriched diet improves immune function not only in the periphery but also in the CNS. Our findings suggest that early intervention with a prebiotic diet systemically enhances metabolism and reduces inflammation.</p>
<p>The systemic changes produced by dietary inulin may help reduce the risk for AD over time. Although AD is a neurodegenerative disorder, accumulating evidence suggests that systemic metabolic dysfunction and inflammation contribute greatly to AD risk. This leaves individuals with insulin resistance, T2DM, hyperlipidemia, obesity, or other metabolic diseases at an increased risk for AD [<xref ref-type="bibr" rid="pone.0221828.ref003">3</xref>]. SCFA deficiency has been associated with T2DM; metabolic dysfunction including inflammation, insulin resistance and endoplasmic reticulum stress, are known to underlie T2DM in peripheral tissues [<xref ref-type="bibr" rid="pone.0221828.ref073">73</xref>]. A similar condition has also been described in the brains of AD patients. In line with this, some groups have even described AD as Type 3 diabetes mellitus (T3DM) [<xref ref-type="bibr" rid="pone.0221828.ref074">74</xref>]. Interventions that could alleviate inflammation and restore metabolic function systemically may ultimately reduce the risk of T2DM and AD. Interestingly, inulin was recently shown to have beneficial effects towards metabolic syndrome in individuals with T2DM by reducing the levels of proinflammatory cytokines (e.g., TNF-&#945; and IL-6) and insulin resistance, thereby lowering blood pressure and improving the lipid profile and glucose homeostasis [<xref ref-type="bibr" rid="pone.0221828.ref075">75</xref>]. Other clinical trials have shown similarly that increased intake of dietary fiber (indigestible but fermentable carbohydrates) was sufficient to induce metabolic improvements in patients with T2DM [<xref ref-type="bibr" rid="pone.0221828.ref008">8</xref>&#8211;<xref ref-type="bibr" rid="pone.0221828.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0221828.ref076">76</xref>]. In line with this, a recent study showed that probiotics were able to counteract AD progression by modulating gut microbiome, reducing inflammatory cytokines, increasing SCFAs and elevating neuroprotective gut hormones [<xref ref-type="bibr" rid="pone.0221828.ref016">16</xref>]. These findings in humans are consistent with the results from our current mouse study. Recent studies demonstrating that treatment of systemic inflammation and metabolic dysfunction can reverse cognitive decline and prevent development of AD [<xref ref-type="bibr" rid="pone.0221828.ref077">77</xref>] encourage us to anticipate that long-term inulin treatment can reduce the risk of developing AD.</p>
<p>In the present study, we show that inulin was able to enhance systemic metabolism by modulating gut microbiome even before the development of A&#946; in the E4FAD mice. In the future, it will be interesting to know if inulin is also able to halt the progression of A&#946; after AD has developed. It will also be interesting to identify if inulin is effective in counteracting other AD pathologies, such as tau tangles, with other animal models. Finally, it will important to determine whether APOE4 protein level also changes due to Inulin and whether the metabolic responses to inulin are dose-dependent (e.g., 4% vs 8% inulin).</p>
</sec>
<sec id="sec028" sec-type="conclusions">
<title>Conclusion</title>
<p>In this study, we detail how a dietary intervention with inulin, a prebiotic, can effectively alter the gut microbiome in a preclinical AD mouse model, enhance systemic metabolic functions and reduce brain inflammation characteristic of early AD. We focus on the underlying metabolic features contributed by the <italic>APOE &#949;4</italic> genotype, the largest risk factor for the development of AD, and show how dietary inulin intervention can mitigate them. This represents a shift in AD research, from the amyloid hypothesis to the metabolic features underlying the disease. As impairment of energy metabolism and elevation of neuroinflammation are well-established features of AD, a prebiotic-rich diet might be a potentially useful approach to prevent the onset of the disease. For future studies, it will be important to establish whether an inulin-enriched diet can inhibit A&#946; aggregation and impede cognitive decline in symptomatic <italic>E4</italic>FAD mice. Understanding the dietary effects in the context of the gut-brain axis may have significant future implications for preventing AD in asymptomatic <italic>APOE4</italic> carriers.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0221828.ref001"><label>1</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bloom</surname> <given-names>GS</given-names></name>. <article-title>Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis</article-title>. <source>JAMA Neurol</source>. <year>2014</year>;<volume>71</volume>(<issue>4</issue>):<fpage>505</fpage>&#8211;<lpage>8</lpage>. Epub 2014/02/05. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1001/jamaneurol.2013.5847" ns0:type="simple">10.1001/jamaneurol.2013.5847</ext-link></comment> <object-id pub-id-type="pmid">24493463</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref002"><label>2</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Modrego</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lobo</surname> <given-names>A</given-names></name>. <article-title>A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned</article-title>. <source>Neurodegenerative disease management</source>. <year>2019</year>. Epub 2019/05/23. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.2217/nmt-2019-0006" ns0:type="simple">10.2217/nmt-2019-0006</ext-link></comment> <object-id pub-id-type="pmid">31116074</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref003"><label>3</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Craft</surname> <given-names>S.</given-names></name> <article-title>The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged</article-title>. <source>Arch Neurol</source>. <year>2009</year>;<volume>66</volume>(<issue>3</issue>):<fpage>300</fpage>&#8211;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1001/archneurol.2009.27" ns0:type="simple">10.1001/archneurol.2009.27</ext-link></comment> <object-id pub-id-type="pmid">19273747</object-id>; PubMed Central PMCID: PMC2717716.</mixed-citation></ref>
<ref id="pone.0221828.ref004"><label>4</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Ishii</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Iadecola</surname> <given-names>C</given-names></name>. <article-title>Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology</article-title>. <source>Cell metabolism</source>. <year>2015</year>;<volume>22</volume>(<issue>5</issue>):<fpage>761</fpage>&#8211;<lpage>76</lpage>. Epub 2015/09/15. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.cmet.2015.08.016" ns0:type="simple">10.1016/j.cmet.2015.08.016</ext-link></comment> <object-id pub-id-type="pmid">26365177</object-id>; PubMed Central PMCID: PMC4654127.</mixed-citation></ref>
<ref id="pone.0221828.ref005"><label>5</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Parbo</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Ismail</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Sommerauer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Stokholm</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>KV</given-names></name>, <etal>et al</etal>. <article-title>Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study</article-title>. <source>Neurobiology of disease</source>. <year>2018</year>;<volume>117</volume>:<fpage>211</fpage>&#8211;<lpage>6</lpage>. Epub 2018/06/15. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.nbd.2018.06.004" ns0:type="simple">10.1016/j.nbd.2018.06.004</ext-link></comment> <object-id pub-id-type="pmid">29902557</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref006"><label>6</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Raber</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ashford</surname> <given-names>JW</given-names></name>. <article-title>ApoE genotype accounts for the vast majority of AD risk and AD pathology</article-title>. <source>Neurobiology of aging</source>. <year>2004</year>;<volume>25</volume>(<issue>5</issue>):<fpage>641</fpage>&#8211;<lpage>50</lpage>. Epub 2004/06/03. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.neurobiolaging.2003.12.023" ns0:type="simple">10.1016/j.neurobiolaging.2003.12.023</ext-link></comment> <object-id pub-id-type="pmid">15172743</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref007"><label>7</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Reiman</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Alexander</surname> <given-names>GE</given-names></name>, <name name-style="western"><surname>Caselli</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Bandy</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Osborne</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2005</year>;<volume>102</volume>(<issue>23</issue>):<fpage>8299</fpage>&#8211;<lpage>302</lpage>. Epub 2005/06/04. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1073/pnas.0500579102" ns0:type="simple">10.1073/pnas.0500579102</ext-link></comment> <object-id pub-id-type="pmid">15932949</object-id>; PubMed Central PMCID: PMC1149416.</mixed-citation></ref>
<ref id="pone.0221828.ref008"><label>8</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Hauptmann</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Scherping</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Drose</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Brandt</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Schulz</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Jendrach</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice</article-title>. <source>Neurobiology of aging</source>. <year>2009</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1574</fpage>&#8211;<lpage>86</lpage>. Epub 2008/02/26. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.neurobiolaging.2007.12.005" ns0:type="simple">10.1016/j.neurobiolaging.2007.12.005</ext-link></comment> <object-id pub-id-type="pmid">18295378</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref009"><label>9</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Johnson</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Torres</surname> <given-names>ER</given-names></name>, <name name-style="western"><surname>Impey</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stevens</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Raber</surname> <given-names>J</given-names></name>. <article-title>Apolipoprotein E4 and Insulin Resistance Interact to Impair Cognition and Alter the Epigenome and Metabolome</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>43701</fpage>. Epub 2017/03/09. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/srep43701" ns0:type="simple">10.1038/srep43701</ext-link></comment> <object-id pub-id-type="pmid">28272510</object-id>; PubMed Central PMCID: PMC5341123.</mixed-citation></ref>
<ref id="pone.0221828.ref010"><label>10</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Torres-Perez</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ledesma</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Garcia-Sobreviela</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Leon-Latre</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Arbones-Mainar</surname> <given-names>JM</given-names></name>. <article-title>Apolipoprotein E4 association with metabolic syndrome depends on body fatness</article-title>. <source>Atherosclerosis</source>. <year>2016</year>;<volume>245</volume>:<fpage>35</fpage>&#8211;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.atherosclerosis.2015.11.029" ns0:type="simple">10.1016/j.atherosclerosis.2015.11.029</ext-link></comment> <object-id pub-id-type="pmid">26691908</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref011"><label>11</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Tao</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Ang</surname> <given-names>TFA</given-names></name>, <name name-style="western"><surname>DeCarli</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Auerbach</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Devine</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Stein</surname> <given-names>TD</given-names></name>, <etal>et al</etal>. <article-title>Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers</article-title>. <source>JAMA Netw Open</source>. <year>2018</year>;<volume>1</volume>(<issue>6</issue>):<fpage>e183597</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1001/jamanetworkopen.2018.3597" ns0:type="simple">10.1001/jamanetworkopen.2018.3597</ext-link></comment> <object-id pub-id-type="pmid">30646251</object-id>; PubMed Central PMCID: PMC6324596.</mixed-citation></ref>
<ref id="pone.0221828.ref012"><label>12</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Minter</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Leone</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Ringus</surname> <given-names>DL</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Oyler-Castrillo</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>30028</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/srep30028" ns0:type="simple">10.1038/srep30028</ext-link></comment> <object-id pub-id-type="pmid">27443609</object-id>; PubMed Central PMCID: PMC4956742.</mixed-citation></ref>
<ref id="pone.0221828.ref013"><label>13</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Nicholson</surname> <given-names>JK</given-names></name>, <name name-style="western"><surname>Holmes</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Kinross</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Burcelin</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Gibson</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Jia</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Host-gut microbiota metabolic interactions</article-title>. <source>Science</source>. <year>2012</year>;<volume>336</volume>(<issue>6086</issue>):<fpage>1262</fpage>&#8211;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1126/science.1223813" ns0:type="simple">10.1126/science.1223813</ext-link></comment> <object-id pub-id-type="pmid">22674330</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref014"><label>14</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Nuzzo</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Amato</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Picone</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Terzo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Galizzi</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bonina</surname> <given-names>FP</given-names></name>, <etal>et al</etal>. <article-title>A Natural Dietary Supplement with a Combination of Nutrients Prevents Neurodegeneration Induced by a High Fat Diet in Mice</article-title>. <source>Nutrients</source>. <year>2018</year>;<volume>10</volume>(<issue>9</issue>). Epub 2018/08/24. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3390/nu10091130" ns0:type="simple">10.3390/nu10091130</ext-link></comment> <object-id pub-id-type="pmid">30134549</object-id>; PubMed Central PMCID: PMC6165339.</mixed-citation></ref>
<ref id="pone.0221828.ref015"><label>15</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Amato</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Caldara</surname> <given-names>GF</given-names></name>, <name name-style="western"><surname>Nuzzo</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Baldassano</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Picone</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Rizzo</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet</article-title>. <source>Nutrients</source>. <year>2017</year>;<volume>9</volume>(<issue>5</issue>). Epub 2017/05/16. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3390/nu9050492" ns0:type="simple">10.3390/nu9050492</ext-link></comment> <object-id pub-id-type="pmid">28505074</object-id>; PubMed Central PMCID: PMC5452222.</mixed-citation></ref>
<ref id="pone.0221828.ref016"><label>16</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bonfili</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Cecarini</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Berardi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Scarpona</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Suchodolski</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Nasuti</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>2426</fpage>. Epub 2017/05/27. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/s41598-017-02587-2" ns0:type="simple">10.1038/s41598-017-02587-2</ext-link></comment> <object-id pub-id-type="pmid">28546539</object-id>; PubMed Central PMCID: PMC5445077.</mixed-citation></ref>
<ref id="pone.0221828.ref017"><label>17</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Nicholson</surname> <given-names>JK</given-names></name>, <name name-style="western"><surname>Wilson</surname> <given-names>ID</given-names></name>. <article-title>Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism</article-title>. <source>Nat Rev Drug Discov</source>. <year>2003</year>;<volume>2</volume>(<issue>8</issue>):<fpage>668</fpage>&#8211;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/nrd1157" ns0:type="simple">10.1038/nrd1157</ext-link></comment> <object-id pub-id-type="pmid">12904817</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref018"><label>18</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Correa-Oliveira</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Fachi</surname> <given-names>JL</given-names></name>, <name name-style="western"><surname>Vieira</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Sato</surname> <given-names>FT</given-names></name>, <name name-style="western"><surname>Vinolo</surname> <given-names>MA</given-names></name>. <article-title>Regulation of immune cell function by short-chain fatty acids</article-title>. <source>Clin Transl Immunology</source>. <year>2016</year>;<volume>5</volume>(<issue>4</issue>):<fpage>e73</fpage>. Epub 2016/05/20. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/cti.2016.17" ns0:type="simple">10.1038/cti.2016.17</ext-link></comment> <object-id pub-id-type="pmid">27195116</object-id>; PubMed Central PMCID: PMC4855267.</mixed-citation></ref>
<ref id="pone.0221828.ref019"><label>19</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Joyce</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>MacSharry</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Casey</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Kinsella</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Murphy</surname> <given-names>EF</given-names></name>, <name name-style="western"><surname>Shanahan</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2014</year>;<volume>111</volume>(<issue>20</issue>):<fpage>7421</fpage>&#8211;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1073/pnas.1323599111" ns0:type="simple">10.1073/pnas.1323599111</ext-link></comment> <object-id pub-id-type="pmid">24799697</object-id>; PubMed Central PMCID: PMC4034235.</mixed-citation></ref>
<ref id="pone.0221828.ref020"><label>20</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Govindarajan</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>MacSharry</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Casey</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Shanahan</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Joyce</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Gahan</surname> <given-names>CG</given-names></name>. <article-title>Unconjugated Bile Acids Influence Expression of Circadian Genes: A Potential Mechanism for Microbe-Host Crosstalk</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>12</issue>):<fpage>e0167319</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0167319" ns0:type="simple">10.1371/journal.pone.0167319</ext-link></comment> <object-id pub-id-type="pmid">27907092</object-id>; PubMed Central PMCID: PMC5132238.</mixed-citation></ref>
<ref id="pone.0221828.ref021"><label>21</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Chyan</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>Poeggeler</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Omar</surname> <given-names>RA</given-names></name>, <name name-style="western"><surname>Chain</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Frangione</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ghiso</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid</article-title>. <source>J Biol Chem</source>. <year>1999</year>;<volume>274</volume>(<issue>31</issue>):<fpage>21937</fpage>&#8211;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1074/jbc.274.31.21937" ns0:type="simple">10.1074/jbc.274.31.21937</ext-link></comment> <object-id pub-id-type="pmid">10419516</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref022"><label>22</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Tse</surname> <given-names>JKY</given-names></name>. <article-title>Gut Microbiota, Nitric Oxide, and Microglia as Prerequisites for Neurodegenerative Disorders</article-title>. <source>ACS Chem Neurosci</source>. <year>2017</year>;<volume>8</volume>(<issue>7</issue>):<fpage>1438</fpage>&#8211;<lpage>47</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1021/acschemneuro.7b00176" ns0:type="simple">10.1021/acschemneuro.7b00176</ext-link></comment> <object-id pub-id-type="pmid">28640632</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref023"><label>23</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Kelly</surname> <given-names>G.</given-names></name> <article-title>Inulin-type prebiotics&#8212;a review: part 1</article-title>. <source>Altern Med Rev</source>. <year>2008</year>;<volume>13</volume>(<issue>4</issue>):<fpage>315</fpage>&#8211;<lpage>29</lpage>. <object-id pub-id-type="pmid">19152479</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref024"><label>24</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Pourghassem Gargari</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Dehghan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Aliasgharzadeh</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Asghari Jafar-Abadi</surname> <given-names>M</given-names></name>. <article-title>Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes</article-title>. <source>Diabetes Metab J</source>. <year>2013</year>;<volume>37</volume>(<issue>2</issue>):<fpage>140</fpage>&#8211;<lpage>8</lpage>. Epub 2013/05/04. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.4093/dmj.2013.37.2.140" ns0:type="simple">10.4093/dmj.2013.37.2.140</ext-link></comment> <object-id pub-id-type="pmid">23641355</object-id>; PubMed Central PMCID: PMC3638225.</mixed-citation></ref>
<ref id="pone.0221828.ref025"><label>25</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Youmans</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Tai</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Nwabuisi-Heath</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Jungbauer</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kanekiyo</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Gan</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>50</issue>):<fpage>41774</fpage>&#8211;<lpage>86</lpage>. Epub 2012/10/13. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1074/jbc.M112.407957" ns0:type="simple">10.1074/jbc.M112.407957</ext-link></comment> <object-id pub-id-type="pmid">23060451</object-id>; PubMed Central PMCID: PMC3516726.</mixed-citation></ref>
<ref id="pone.0221828.ref026"><label>26</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Tai</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Balu</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Avila-Munoz</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Abdullah</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Thomas</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Collins</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease</article-title>. <source>J Lipid Res</source>. <year>2017</year>;<volume>58</volume>(<issue>9</issue>):<fpage>1733</fpage>&#8211;<lpage>55</lpage>. Epub 2017/04/09. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1194/jlr.R076315" ns0:type="simple">10.1194/jlr.R076315</ext-link></comment> <object-id pub-id-type="pmid">28389477</object-id>; PubMed Central PMCID: PMC5580905.</mixed-citation></ref>
<ref id="pone.0221828.ref027"><label>27</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Trautwein</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Rieckhoff</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Erbersdobler</surname> <given-names>HF</given-names></name>. <article-title>Dietary inulin lowers plasma cholesterol and triacylglycerol and alters biliary bile acid profile in hamsters</article-title>. <source>J Nutr</source>. <year>1998</year>;<volume>128</volume>(<issue>11</issue>):<fpage>1937</fpage>&#8211;<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/jn/128.11.1937" ns0:type="simple">10.1093/jn/128.11.1937</ext-link></comment> <object-id pub-id-type="pmid">9808646</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref028"><label>28</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Zdunczyk</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Juskiewicz</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wroblewska</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Krol</surname> <given-names>B</given-names></name>. <article-title>Physiological effects of lactulose and inulin in the caecum of rats</article-title>. <source>Arch Anim Nutr</source>. <year>2004</year>;<volume>58</volume>(<issue>1</issue>):<fpage>89</fpage>&#8211;<lpage>98</lpage>. Epub 2004/04/17. <object-id pub-id-type="pmid">15085967</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref029"><label>29</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Coudray</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bellanger</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Castiglia-Delavaud</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Remesy</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Vermorel</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Rayssignuier</surname> <given-names>Y</given-names></name>. <article-title>Effect of soluble or partly soluble dietary fibres supplementation on absorption and balance of calcium, magnesium, iron and zinc in healthy young men</article-title>. <source>Eur J Clin Nutr</source>. <year>1997</year>;<volume>51</volume>(<issue>6</issue>):<fpage>375</fpage>&#8211;<lpage>80</lpage>. Epub 1997/06/01. <object-id pub-id-type="pmid">9192195</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref030"><label>30</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Laukens</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Brinkman</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Raes</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>De Vos</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Vandenabeele</surname> <given-names>P</given-names></name>. <article-title>Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design</article-title>. <source>FEMS Microbiol Rev</source>. <year>2016</year>;<volume>40</volume>(<issue>1</issue>):<fpage>117</fpage>&#8211;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/femsre/fuv036" ns0:type="simple">10.1093/femsre/fuv036</ext-link></comment> <object-id pub-id-type="pmid">26323480</object-id>; PubMed Central PMCID: PMC4703068.</mixed-citation></ref>
<ref id="pone.0221828.ref031"><label>31</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Guo</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bakshi</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>AL</given-names></name>. <article-title>Early Shifts of Brain Metabolism by Caloric Restriction Preserve White Matter Integrity and Long-Term Memory in Aging Mice</article-title>. <source>Front Aging Neurosci</source>. <year>2015</year>;<volume>7</volume>:<fpage>213</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3389/fnagi.2015.00213" ns0:type="simple">10.3389/fnagi.2015.00213</ext-link></comment> <object-id pub-id-type="pmid">26617514</object-id>; PubMed Central PMCID: PMC4643125.</mixed-citation></ref>
<ref id="pone.0221828.ref032"><label>32</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Eagan</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Gonzales</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Tarumi</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Stautberg</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Haley</surname> <given-names>AP</given-names></name>. <article-title>Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults</article-title>. <source>Cardiovasc Psychiatry Neurol</source>. <year>2012</year>;<volume>2012</volume>:<fpage>120540</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1155/2012/120540" ns0:type="simple">10.1155/2012/120540</ext-link></comment> <object-id pub-id-type="pmid">22461977</object-id>; PubMed Central PMCID: PMC3296271.</mixed-citation></ref>
<ref id="pone.0221828.ref033"><label>33</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Green</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Venkatramanan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Naqib</surname> <given-names>A</given-names></name>. <article-title>Deconstructing the polymerase chain reaction: understanding and correcting bias associated with primer degeneracies and primer-template mismatches</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e0128122</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0128122" ns0:type="simple">10.1371/journal.pone.0128122</ext-link></comment> <object-id pub-id-type="pmid">25996930</object-id>; PubMed Central PMCID: PMC4440812.</mixed-citation></ref>
<ref id="pone.0221828.ref034"><label>34</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Zhang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kobert</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Flouri</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Stamatakis</surname> <given-names>A</given-names></name>. <article-title>PEAR: a fast and accurate Illumina Paired-End reAd mergeR</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>30</volume>(<issue>5</issue>):<fpage>614</fpage>&#8211;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/bioinformatics/btt593" ns0:type="simple">10.1093/bioinformatics/btt593</ext-link></comment> <object-id pub-id-type="pmid">24142950</object-id>; PubMed Central PMCID: PMC3933873.</mixed-citation></ref>
<ref id="pone.0221828.ref035"><label>35</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Caporaso</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Kuczynski</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Stombaugh</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Bittinger</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Bushman</surname> <given-names>FD</given-names></name>, <name name-style="western"><surname>Costello</surname> <given-names>EK</given-names></name>, <etal>et al</etal>. <article-title>QIIME allows analysis of high-throughput community sequencing data</article-title>. <source>Nat Methods</source>. <year>2010</year>;<volume>7</volume>(<issue>5</issue>):<fpage>335</fpage>&#8211;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/nmeth.f.303" ns0:type="simple">10.1038/nmeth.f.303</ext-link></comment> <object-id pub-id-type="pmid">20383131</object-id>; PubMed Central PMCID: PMC3156573.</mixed-citation></ref>
<ref id="pone.0221828.ref036"><label>36</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Edgar</surname> <given-names>RC</given-names></name>. <article-title>Search and clustering orders of magnitude faster than BLAST</article-title>. <source>Bioinformatics</source>. <year>2010</year>;<volume>26</volume>(<issue>19</issue>):<fpage>2460</fpage>&#8211;<lpage>1</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/bioinformatics/btq461" ns0:type="simple">10.1093/bioinformatics/btq461</ext-link></comment> <object-id pub-id-type="pmid">20709691</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref037"><label>37</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>McDonald</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Price</surname> <given-names>MN</given-names></name>, <name name-style="western"><surname>Goodrich</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nawrocki</surname> <given-names>EP</given-names></name>, <name name-style="western"><surname>DeSantis</surname> <given-names>TZ</given-names></name>, <name name-style="western"><surname>Probst</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea</article-title>. <source>ISME J</source>. <year>2012</year>;<volume>6</volume>(<issue>3</issue>):<fpage>610</fpage>&#8211;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/ismej.2011.139" ns0:type="simple">10.1038/ismej.2011.139</ext-link></comment> <object-id pub-id-type="pmid">22134646</object-id>; PubMed Central PMCID: PMC3280142.</mixed-citation></ref>
<ref id="pone.0221828.ref038"><label>38</label><mixed-citation publication-type="book" ns0:type="simple"><name name-style="western"><surname>Oksanen</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Blanchet</surname> <given-names>FG</given-names></name>, <source>Friendly Fea</source>. <publisher-loc>Vegan</publisher-loc>: <publisher-name>Community ecology package</publisher-name>. <year>2016</year>.</mixed-citation></ref>
<ref id="pone.0221828.ref039"><label>39</label><mixed-citation publication-type="book" ns0:type="simple"><name name-style="western"><surname>Hadley</surname> <given-names>W.</given-names></name> <source>Ggplot2</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer Science+Business Media, LLC</publisher-name>; <year>2016</year>. pages cm p.</mixed-citation></ref>
<ref id="pone.0221828.ref040"><label>40</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Evans</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Bridgewater</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Mitchell</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Robinson</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Dai</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>High Resolution Mass Spectrometry Improves Data Quantity and Quality as Compared to Unit Mass Resolution Mass Spectrometry in High- Throughput Profiling Metabolomics</article-title>. <source>Metabolomics</source>. <year>2014</year>;<volume>4</volume>(<issue>132</issue>).</mixed-citation></ref>
<ref id="pone.0221828.ref041"><label>41</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Holmes</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>JV</given-names></name>, <name name-style="western"><surname>Marchesi</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Nicholson</surname> <given-names>JK</given-names></name>. <article-title>Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk</article-title>. <source>Cell metabolism</source>. <year>2012</year>;<volume>16</volume>(<issue>5</issue>):<fpage>559</fpage>&#8211;<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.cmet.2012.10.007" ns0:type="simple">10.1016/j.cmet.2012.10.007</ext-link></comment> <object-id pub-id-type="pmid">23140640</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref042"><label>42</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Evans</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>DeHaven</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Barrett</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Mitchell</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Milgram</surname> <given-names>E</given-names></name>. <article-title>Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems</article-title>. <source>Anal Chem</source>. <year>2009</year>;<volume>81</volume>(<issue>16</issue>):<fpage>6656</fpage>&#8211;<lpage>67</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1021/ac901536h" ns0:type="simple">10.1021/ac901536h</ext-link></comment> <object-id pub-id-type="pmid">19624122</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref043"><label>43</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Krasemann</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Madore</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cialic</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Baufeld</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Calcagno</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>El Fatimy</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases</article-title>. <source>Immunity</source>. <year>2017</year>;<volume>47</volume>(<issue>3</issue>):<fpage>566</fpage>&#8211;<lpage>81</lpage>.e9. Epub 2017/09/21. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.immuni.2017.08.008" ns0:type="simple">10.1016/j.immuni.2017.08.008</ext-link></comment> <object-id pub-id-type="pmid">28930663</object-id>; PubMed Central PMCID: PMC5719893.</mixed-citation></ref>
<ref id="pone.0221828.ref044"><label>44</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Dehaven</surname> <given-names>CD</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Dai</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Lawton</surname> <given-names>KA</given-names></name>. <article-title>Organization of GC/MS and LC/MS metabolomics data into chemical libraries</article-title>. <source>J Cheminform</source>. <year>2010</year>;<volume>2</volume>(<issue>1</issue>):<fpage>9</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1186/1758-2946-2-9" ns0:type="simple">10.1186/1758-2946-2-9</ext-link></comment> <object-id pub-id-type="pmid">20955607</object-id>; PubMed Central PMCID: PMC2984397.</mixed-citation></ref>
<ref id="pone.0221828.ref045"><label>45</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Kovatcheva-Datchary</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Nilsson</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Akrami</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>De Vadder</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Arora</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Dietary Fiber-Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella</article-title>. <source>Cell metabolism</source>. <year>2015</year>;<volume>22</volume>(<issue>6</issue>):<fpage>971</fpage>&#8211;<lpage>82</lpage>. Epub 2015/11/11. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.cmet.2015.10.001" ns0:type="simple">10.1016/j.cmet.2015.10.001</ext-link></comment> <object-id pub-id-type="pmid">26552345</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref046"><label>46</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Walter</surname> <given-names>J.</given-names></name> <article-title>Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research</article-title>. <source>Appl Environ Microbiol</source>. <year>2008</year>;<volume>74</volume>(<issue>16</issue>):<fpage>4985</fpage>&#8211;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/AEM.00753-08" ns0:type="simple">10.1128/AEM.00753-08</ext-link></comment> <object-id pub-id-type="pmid">18539818</object-id>; PubMed Central PMCID: PMC2519286.</mixed-citation></ref>
<ref id="pone.0221828.ref047"><label>47</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Sharon</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Garg</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Debelius</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Knight</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Dorrestein</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Mazmanian</surname> <given-names>SK</given-names></name>. <article-title>Specialized metabolites from the microbiome in health and disease</article-title>. <source>Cell metabolism</source>. <year>2014</year>;<volume>20</volume>(<issue>5</issue>):<fpage>719</fpage>&#8211;<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.cmet.2014.10.016" ns0:type="simple">10.1016/j.cmet.2014.10.016</ext-link></comment> <object-id pub-id-type="pmid">25440054</object-id>; PubMed Central PMCID: PMC4337795.</mixed-citation></ref>
<ref id="pone.0221828.ref048"><label>48</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Desai</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Seekatz</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Koropatkin</surname> <given-names>NM</given-names></name>, <name name-style="western"><surname>Kamada</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hickey</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Wolter</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility</article-title>. <source>Cell</source>. <year>2016</year>;<volume>167</volume>(<issue>5</issue>):<fpage>1339</fpage>&#8211;<lpage>53</lpage> e21. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.cell.2016.10.043" ns0:type="simple">10.1016/j.cell.2016.10.043</ext-link></comment> <object-id pub-id-type="pmid">27863247</object-id>; PubMed Central PMCID: PMC5131798.</mixed-citation></ref>
<ref id="pone.0221828.ref049"><label>49</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Chen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Long</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Hamaker</surname> <given-names>BR</given-names></name>. <article-title>Fiber-utilizing capacity varies in Prevotella- versus Bacteroides-dominated gut microbiota</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>2594</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/s41598-017-02995-4" ns0:type="simple">10.1038/s41598-017-02995-4</ext-link></comment> <object-id pub-id-type="pmid">28572676</object-id>; PubMed Central PMCID: PMC5453967.</mixed-citation></ref>
<ref id="pone.0221828.ref050"><label>50</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Nishitsuji</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nagatomo</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Umemoto</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Morimoto</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Akatsu</surname> <given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Analysis of the gut microbiome and plasma short-chain fatty acid profiles in a spontaneous mouse model of metabolic syndrome</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>15876</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/s41598-017-16189-5" ns0:type="simple">10.1038/s41598-017-16189-5</ext-link></comment> <object-id pub-id-type="pmid">29158587</object-id>; PubMed Central PMCID: PMC5696507.</mixed-citation></ref>
<ref id="pone.0221828.ref051"><label>51</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Hamilton</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Kamm</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Ng</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Morrison</surname> <given-names>M</given-names></name>. <article-title>Proteus spp. as Putative Gastrointestinal Pathogens</article-title>. <source>Clin Microbiol Rev</source>. <year>2018</year>;<volume>31</volume>(<issue>3</issue>). <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1128/CMR.00085-17" ns0:type="simple">10.1128/CMR.00085-17</ext-link></comment> <object-id pub-id-type="pmid">29899011</object-id>; PubMed Central PMCID: PMC6056842.</mixed-citation></ref>
<ref id="pone.0221828.ref052"><label>52</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Yasuda</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Maiorano</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Welch</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Miller</surname> <given-names>DD</given-names></name>, <name name-style="western"><surname>Lei</surname> <given-names>XG</given-names></name>. <article-title>Cecum is the major degradation site of ingested inulin in young pigs</article-title>. <source>J Nutr</source>. <year>2007</year>;<volume>137</volume>(<issue>11</issue>):<fpage>2399</fpage>&#8211;<lpage>404</lpage>. Epub 2007/10/24. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1093/jn/137.11.2399" ns0:type="simple">10.1093/jn/137.11.2399</ext-link></comment> <object-id pub-id-type="pmid">17951476</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref053"><label>53</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Kuo</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Merhige</surname> <given-names>PM</given-names></name>, <name name-style="western"><surname>Hagey</surname> <given-names>LR</given-names></name>. <article-title>The effect of dietary prebiotics and probiotics on body weight, large intestine indices, and fecal bile acid profile in wild type and IL10-/- mice</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>3</issue>):<fpage>e60270</fpage>. Epub 2013/04/05. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1371/journal.pone.0060270" ns0:type="simple">10.1371/journal.pone.0060270</ext-link></comment> <object-id pub-id-type="pmid">23555939</object-id>; PubMed Central PMCID: PMC3605333.</mixed-citation></ref>
<ref id="pone.0221828.ref054"><label>54</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Blacher</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Levy</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Tatirovsky</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Elinav</surname> <given-names>E</given-names></name>. <article-title>Microbiome-Modulated Metabolites at the Interface of Host Immunity</article-title>. <source>J Immunol</source>. <year>2017</year>;<volume>198</volume>(<issue>2</issue>):<fpage>572</fpage>&#8211;<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.4049/jimmunol.1601247" ns0:type="simple">10.4049/jimmunol.1601247</ext-link></comment> <object-id pub-id-type="pmid">28069752</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref055"><label>55</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Takahashi</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Izawa</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Suzuki</surname> <given-names>N</given-names></name>. <article-title>Astroglial pentose phosphate pathway rates in response to high-glucose environments</article-title>. <source>ASN neuro</source>. <year>2012</year>;<volume>4</volume>(<collab>2</collab>). Epub 2012/02/04. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1042/an20120002" ns0:type="simple">10.1042/an20120002</ext-link></comment> <object-id pub-id-type="pmid">22300409</object-id>; PubMed Central PMCID: PMC3310304.</mixed-citation></ref>
<ref id="pone.0221828.ref056"><label>56</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Sun</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Hawkes</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Shaw</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>McLaurin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nitz</surname> <given-names>M</given-names></name>. <article-title>Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation</article-title>. <source>Bioorg Med Chem</source>. <year>2008</year>;<volume>16</volume>(<issue>15</issue>):<fpage>7177</fpage>&#8211;<lpage>84</lpage>. Epub 2008/07/19. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.bmc.2008.06.045" ns0:type="simple">10.1016/j.bmc.2008.06.045</ext-link></comment> <object-id pub-id-type="pmid">18635362</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref057"><label>57</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Voevodskaya</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Sundgren</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Strandberg</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Zetterberg</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Minthon</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Blennow</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease</article-title>. <source>Neurology</source>. <year>2016</year>;<volume>86</volume>(<issue>19</issue>):<fpage>1754</fpage>&#8211;<lpage>61</lpage>. Epub 2016/05/11. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1212/WNL.0000000000002672" ns0:type="simple">10.1212/WNL.0000000000002672</ext-link></comment> <object-id pub-id-type="pmid">27164711</object-id>; PubMed Central PMCID: PMC4862247.</mixed-citation></ref>
<ref id="pone.0221828.ref058"><label>58</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Rafii</surname> <given-names>MS</given-names></name>, <name name-style="western"><surname>Skotko</surname> <given-names>BG</given-names></name>, <name name-style="western"><surname>McDonough</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>Pulsifer</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Evans</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Doran</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia</article-title>. <source>J Alzheimers Dis</source>. <year>2017</year>;<volume>58</volume>(<issue>2</issue>):<fpage>401</fpage>&#8211;<lpage>11</lpage>. Epub 2017/04/30. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3233/JAD-160965" ns0:type="simple">10.3233/JAD-160965</ext-link></comment> <object-id pub-id-type="pmid">28453471</object-id>; PubMed Central PMCID: PMC5777855.</mixed-citation></ref>
<ref id="pone.0221828.ref059"><label>59</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Oakley</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Cole</surname> <given-names>SL</given-names></name>, <name name-style="western"><surname>Logan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Maus</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Shao</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Craft</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation</article-title>. <source>J Neurosci</source>. <year>2006</year>;<volume>26</volume>(<issue>40</issue>):<fpage>10129</fpage>&#8211;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1523/JNEUROSCI.1202-06.2006" ns0:type="simple">10.1523/JNEUROSCI.1202-06.2006</ext-link></comment> <object-id pub-id-type="pmid">17021169</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref060"><label>60</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Boehme</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>van de Wouw</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bastiaanssen</surname> <given-names>TFS</given-names></name>, <name name-style="western"><surname>Olavarria-Ramirez</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lyons</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Fouhy</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Mid-life microbiota crises: middle age is associated with pervasive neuroimmune alterations that are reversed by targeting the gut microbiome</article-title>. <source>Mol Psychiatry</source>. <year>2019</year>. Epub 2019/05/17. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/s41380-019-0425-1" ns0:type="simple">10.1038/s41380-019-0425-1</ext-link></comment> <object-id pub-id-type="pmid">31092898</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref061"><label>61</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bourassa</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Alim</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Bultman</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Ratan</surname> <given-names>RR</given-names></name>. <article-title>Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health</article-title>? <source>Neurosci Lett</source>. <year>2016</year>;<volume>625</volume>:<fpage>56</fpage>&#8211;<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.neulet.2016.02.009" ns0:type="simple">10.1016/j.neulet.2016.02.009</ext-link></comment> <object-id pub-id-type="pmid">26868600</object-id>; PubMed Central PMCID: PMC4903954.</mixed-citation></ref>
<ref id="pone.0221828.ref062"><label>62</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Trauner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Wagner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fickert</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Zollner</surname> <given-names>G</given-names></name>. <article-title>Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis</article-title>. <source>Journal of clinical gastroenterology</source>. <year>2005</year>;<volume>39</volume>(<issue>4</issue> Suppl 2):<fpage>S111</fpage>&#8211;<lpage>24</lpage>. Epub 2005/03/11. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1097/01.mcg.0000155551.37266.26" ns0:type="simple">10.1097/01.mcg.0000155551.37266.26</ext-link></comment> <object-id pub-id-type="pmid">15758646</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref063"><label>63</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Fooks</surname> <given-names>LJ</given-names></name>, <name name-style="western"><surname>Gibson</surname> <given-names>GR</given-names></name>. <article-title>Probiotics as modulators of the gut flora</article-title>. <source>Br J Nutr</source>. <year>2002</year>;<volume>88</volume> <issue>Suppl 1</issue>:<fpage>S39</fpage>&#8211;<lpage>49</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1079/BJN2002628" ns0:type="simple">10.1079/BJN2002628</ext-link></comment> <object-id pub-id-type="pmid">12215180</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref064"><label>64</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Larsen</surname> <given-names>OFA</given-names></name>, <name name-style="western"><surname>Claassen</surname> <given-names>E</given-names></name>. <article-title>The mechanistic link between health and gut microbiota diversity</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>2183</fpage>. Epub 2018/02/03. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/s41598-018-20141-6" ns0:type="simple">10.1038/s41598-018-20141-6</ext-link></comment> <object-id pub-id-type="pmid">29391457</object-id>; PubMed Central PMCID: PMC5794854.</mixed-citation></ref>
<ref id="pone.0221828.ref065"><label>65</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Hoffman</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Parikh</surname> <given-names>I.</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>S.J.</given-names></name>, <name name-style="western"><surname>Chlipala</surname> <given-names>G.</given-names></name>, <name name-style="western"><surname>Mohney</surname> <given-names>R.P.</given-names></name>, <name name-style="western"><surname>Keaton</surname> <given-names>M.</given-names></name>, <name name-style="western"><surname>Bauer</surname> <given-names>B</given-names></name>,. <name name-style="western"><surname>Hartz</surname> <given-names>A.M.S.</given-names></name> <name name-style="western"><surname>Lin</surname> <given-names>A.L.</given-names></name> <article-title>Age Drives Distortion of BrainMetabolic, Vascular and Cognitive Functions, and the Gut Microbiome</article-title>. <source>Front Aging Neurosci</source>. <year>2017</year>;<volume>9</volume>:<fpage>298</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3389/fnagi.2017.00298" ns0:type="simple">10.3389/fnagi.2017.00298</ext-link></comment> <object-id pub-id-type="pmid">28993728</object-id></mixed-citation></ref>
<ref id="pone.0221828.ref066"><label>66</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Ma</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>AC</given-names></name>, <name name-style="western"><surname>Parikh</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Green</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Hoffman</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Chlipala</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>6670</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/s41598-018-25190-5" ns0:type="simple">10.1038/s41598-018-25190-5</ext-link></comment> <object-id pub-id-type="pmid">29703936</object-id>; PubMed Central PMCID: PMC5923270.</mixed-citation></ref>
<ref id="pone.0221828.ref067"><label>67</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Uronis</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Arthur</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Keku</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Fodor</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Carroll</surname> <given-names>IM</given-names></name>, <name name-style="western"><surname>Cruz</surname> <given-names>ML</given-names></name>, <etal>et al</etal>. <article-title>Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis</article-title>. <source>Inflamm Bowel Dis</source>. <year>2011</year>;<volume>17</volume>(<issue>1</issue>):<fpage>289</fpage>&#8211;<lpage>97</lpage>. Epub 2010/06/22. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1002/ibd.21366" ns0:type="simple">10.1002/ibd.21366</ext-link></comment> <object-id pub-id-type="pmid">20564535</object-id>; PubMed Central PMCID: PMC2953593.</mixed-citation></ref>
<ref id="pone.0221828.ref068"><label>68</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Kang</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Michon</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Morinaga</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Tanaka</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Takenaka</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ishikawa</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Bacillus subtilis IolQ (DegA) is a transcriptional repressor of iolX encoding NAD(+)-dependent scyllo-inositol dehydrogenase</article-title>. <source>BMC Microbiol</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>154</fpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1186/s12866-017-1065-8" ns0:type="simple">10.1186/s12866-017-1065-8</ext-link></comment> <object-id pub-id-type="pmid">28693424</object-id>; PubMed Central PMCID: PMC5504672.</mixed-citation></ref>
<ref id="pone.0221828.ref069"><label>69</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bitsch</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bruhn</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Vougioukas</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Stringaris</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lassmann</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Frahm</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy</article-title>. <source>AJNR Am J Neuroradiol</source>. <year>1999</year>;<volume>20</volume>(<issue>9</issue>):<fpage>1619</fpage>&#8211;<lpage>27</lpage>. <object-id pub-id-type="pmid">10543631</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref070"><label>70</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Zhu</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Allard</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Perez</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Spangler</surname> <given-names>EL</given-names></name>, <name name-style="western"><surname>Becker</surname> <given-names>KG</given-names></name>, <etal>et al</etal>. <article-title>Age-related brain expression and regulation of the chemokine CCL4/MIP-1beta in APP/PS1 double-transgenic mice</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2014</year>;<volume>73</volume>(<issue>4</issue>):<fpage>362</fpage>&#8211;<lpage>74</lpage>. Epub 2014/03/13. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1097/NEN.0000000000000060" ns0:type="simple">10.1097/NEN.0000000000000060</ext-link></comment> <object-id pub-id-type="pmid">24607962</object-id>; PubMed Central PMCID: PMC3977177.</mixed-citation></ref>
<ref id="pone.0221828.ref071"><label>71</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Fuller</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Stavenhagen</surname> <given-names>JB</given-names></name>, <name name-style="western"><surname>Teeling</surname> <given-names>JL</given-names></name>. <article-title>New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease</article-title>. <source>Front Neurosci</source>. <year>2014</year>;<volume>8</volume>:<fpage>235</fpage>. Epub 2014/09/06. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.3389/fnins.2014.00235" ns0:type="simple">10.3389/fnins.2014.00235</ext-link></comment> <object-id pub-id-type="pmid">25191216</object-id>; PubMed Central PMCID: PMC4139653.</mixed-citation></ref>
<ref id="pone.0221828.ref072"><label>72</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Galimberti</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Schoonenboom</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Scheltens</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Fenoglio</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bouwman</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Venturelli</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease</article-title>. <source>Arch Neurol</source>. <year>2006</year>;<volume>63</volume>(<issue>4</issue>):<fpage>538</fpage>&#8211;<lpage>43</lpage>. Epub 2006/04/12. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1001/archneur.63.4.538" ns0:type="simple">10.1001/archneur.63.4.538</ext-link></comment> <object-id pub-id-type="pmid">16606766</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref073"><label>73</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Hotamisligil</surname> <given-names>GS</given-names></name>. <article-title>Inflammation and metabolic disorders</article-title>. <source>Nature</source>. <year>2006</year>;<volume>444</volume>(<issue>7121</issue>):<fpage>860</fpage>&#8211;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1038/nature05485" ns0:type="simple">10.1038/nature05485</ext-link></comment> <object-id pub-id-type="pmid">17167474</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref074"><label>74</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Leszek</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Trypka</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Tarasov</surname> <given-names>VV</given-names></name>, <name name-style="western"><surname>Ashraf</surname> <given-names>GM</given-names></name>, <name name-style="western"><surname>Aliev</surname> <given-names>G</given-names></name>. <article-title>Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease</article-title>. <source>Current topics in medicinal chemistry</source>. <year>2017</year>;<volume>17</volume>(<issue>12</issue>):<fpage>1331</fpage>&#8211;<lpage>5</lpage>. Epub 2017/01/05. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.2174/1568026617666170103163403" ns0:type="simple">10.2174/1568026617666170103163403</ext-link></comment> <object-id pub-id-type="pmid">28049395</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref075"><label>75</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>O'Connor</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Chouinard-Castonguay</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gagnon</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Rudkowska</surname> <given-names>I</given-names></name>. <article-title>Prebiotics in the management of components of the metabolic syndrome</article-title>. <source>Maturitas</source>. <year>2017</year>;<volume>104</volume>:<fpage>11</fpage>&#8211;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.maturitas.2017.07.005" ns0:type="simple">10.1016/j.maturitas.2017.07.005</ext-link></comment> <object-id pub-id-type="pmid">28923170</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref076"><label>76</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Zhao</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Ding</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Lam</surname> <given-names>YY</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes</article-title>. <source>Science</source>. <year>2018</year>;<volume>359</volume>(<issue>6380</issue>):<fpage>1151</fpage>&#8211;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1126/science.aao5774" ns0:type="simple">10.1126/science.aao5774</ext-link></comment> <object-id pub-id-type="pmid">29590046</object-id>.</mixed-citation></ref>
<ref id="pone.0221828.ref077"><label>77</label><mixed-citation publication-type="journal" ns0:type="simple"><name name-style="western"><surname>Bredesen</surname> <given-names>DE</given-names></name>, <name name-style="western"><surname>Amos</surname> <given-names>EC</given-names></name>, <name name-style="western"><surname>Canick</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ackerley</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Raji</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fiala</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Reversal of cognitive decline in Alzheimer's disease</article-title>. <source>Aging (Albany NY)</source>. <year>2016</year>;<volume>8</volume>(<issue>6</issue>):<fpage>1250</fpage>&#8211;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.18632/aging.100981" ns0:type="simple">10.18632/aging.100981</ext-link></comment> <object-id pub-id-type="pmid">27294343</object-id>; PubMed Central PMCID: PMC4931830.</mixed-citation></ref>
</ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0221828.r001" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0221828.r001</article-id>
<title-group>
<article-title>Decision Letter 0</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Reichmann</surname>
<given-names>Florian</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Florian Reichmann</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0221828" document-id-type="doi" document-type="article" id="rel-obj001" link-type="peer-reviewed-article" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>0</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">30 Jul 2019</named-content>
</p>
<p>PONE-D-19-17293</p>
<p>Dietary inulin alters the gut microbiome, enhances systemic metabolism and reduces neuroinflammation in an APOE4 relevant mouse model of preclinical Alzheimer&#8217;s Disease</p>
<p>PLOS ONE</p>
<p>Dear Prof. Ai-Ling Lin,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE&#8217;s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>We would appreciate receiving your revised manuscript by 13th of September. When you are ready to submit your revision, log on to <ext-link ext-link-type="uri" ns0:href="https://www.editorialmanager.com/pone/" ns0:type="simple">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.</p>
<p>To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <ext-link ext-link-type="uri" ns0:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ns0:type="simple">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link></p>
<p>Please include the following items when submitting your revised manuscript:</p>
<p><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.</p></list-item></list></p>
<p>Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Florian Reichmann, M.D., Ph.D.</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Journal Requirements:</p>
<p>1. When submitting your revision, we need you to address these additional requirements.</p>
<p>Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
<p><ext-link ext-link-type="uri" ns0:href="http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ns0:type="simple">http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and <ext-link ext-link-type="uri" ns0:href="http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ns0:type="simple">http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link></p>
<p>2. We note that your article has been submitted as a "Collection Review" article type, but is primary research submitted for a Call for Papers. When resubmitting your manuscript, we ask that you update your article type to "Research Article" in the online submission form. Please note that some fields in the submission form, particularly in the "Additional Information" field, will have been reset with this change, so please go through your submission in full to ensure that all information is accurate and complete when resubmitting your manuscript.</p>
<p>3. At this time, we request that you please include the method of euthanasia and the source of the animals in your Methods section. We also ask that you please include your ethics information " All experimental procedures were performed according to NIH guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Kentucky (UK)." in the on-line ethics statement on the details page. Thank you for your attention to these requests.</p>
<p>4. Thank you for stating the following in the Competing Interests section:</p>
<p>[Scott McCulloch is employed by Metabolon Inc. All other authors have declared that no competing interests exist.].&#160;&#160;&#160;</p>
<p>We note that one or more of the authors are employed by a commercial company: 'Metabolon Inc'.</p>
<p><list list-type="order"><list-item><p>Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.</p></list-item></list></p>
<p>* Please also include the following statement within your amended Funding Statement.</p>
<p>&#8220;The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the &#8216;author contributions&#8217; section.&#8221;</p>
<p>If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.</p>
<p>2. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc. &#160;</p>
<p>Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to&#160; PLOS ONE policies on sharing data and materials.&#8221; (as detailed online in our guide for authors <ext-link ext-link-type="uri" ns0:href="http://journals.plos.org/plosone/s/competing-interests" ns0:type="simple">http://journals.plos.org/plosone/s/competing-interests</ext-link>) . If this adherence statement is not accurate and&#160; there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.</p>
<p>* Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.</p>
<p>Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <ext-link ext-link-type="uri" ns0:href="http://journals.plos.org/plosone/s/competing-interests" ns0:type="simple">http://journals.plos.org/plosone/s/competing-interests</ext-link></p>
<p>Additional Editor Comments (if provided):</p>
<p>Reviewer #1: This is a very interesting paper showing how preserving metabolic function through microbiota modulation AD risk can be reduced.</p>
<p>In my opinion the author should mention recent papers demonstrating that upon probiotics administration AD progression is counteracted based on microbiota modulation, reduction of inflammatory cytokinesm increased SCFAs, increased neuroprotective gut hormones (Bonfili L. et al. Scientific Reports 2017)</p>
<p>Reviewer #2: 1 The expression of APOE4 should be included after the adminstration of inulin. And more AD biomaker as Tau, BACE, p-Tau, or histopathology of brain and colon.</p>
<p>2 I think there are at lest two does of inulin treated groups should be proved.</p>
<p>3 What the dose judgment, 8% of inulin? AS: Vishal Singh et al., (2018), Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer, Cell, DOI: <ext-link ext-link-type="uri" ns0:href="https://doi.org/10.1016/j.cell.2018.09.004" ns0:type="simple">https://doi.org/10.1016/j.cell.2018.09.004</ext-link>.</p>
<p>4 More the correction analysis bteween the AD biomaker and gut microbiota, Metabolite.</p>
<p>5 Are the metabolite of Scyllo-inositol and myo-inositol is related to AD?</p>
<p>Reviewer #3: In their manuscript, the Authors have investigated the neuroprotective role of inulin ingestion by in vivo tests on E4FAD mice. The Authors have demonstrated that inulin has beneficial effects on microbiota and neuroinflammation. In fact, the experiments were performed to demonstrate that inulin compound have an anti-neurodegenerative role in mice fed with inulin diet. The topic is really interesting and the experiments are well designed. For this reason, I suggest only some corrections.</p>
<p>1. The references Nuzzo D, et al. Nutrients 2018 and Amato A et al. Nutrients 2017 should be added in the introduction to describe the link between oxidative stress and diseases.</p>
<p>2. I suggest to give more information regarding the mouse treatment. The Authors may add some additional information like food consumption (g for a day) and total caloric intake. How many grams of inulin are daily supplied to mice?</p>
<p>3. In Figure 1(D) the image of E3-control is missing.</p>
<p>4. The title of the article is inappropriate because the data reported are insufficient to claim a potential role of inulin for the Alzheimer disease. I suggest to remove "[&#8230;] relevant mouse model of preclinical Alzheimer's Disease" from the title.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link ext-link-type="uri" ns0:href="https://pacev2.apexcovantage.com/" ns0:type="simple">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <email ns0:type="simple">figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
</body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0221828.r002">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0221828.r002</article-id>
<title-group>
<article-title>Author response to Decision Letter 0</article-title>
</title-group>
<related-object document-id="10.1371/journal.pone.0221828" document-id-type="doi" document-type="peer-reviewed-article" id="rel-obj002" link-type="rebutted-decision-letter" object-id="10.1371/journal.pone.0221828.r001" object-id-type="doi" object-type="decision-letter" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="author-response-date">12 Aug 2019</named-content>
</p>
<p>We have included the point-by-point response to the reviewer's comments in a separate file. We also addressed to the editor's request by adding the method of euthanasia and the source of the animals in our Methods section.</p>
<supplementary-material id="pone.0221828.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" ns0:href="info:doi/10.1371/journal.pone.0221828.s001" ns0:type="simple">
<label>Attachment</label>
<caption>
<p>Submitted filename: <named-content content-type="submitted-filename">Inulin Rebuttal Letter_08.06.19_final_rev.docx</named-content></p>
</caption>
</supplementary-material>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0221828.r003" specific-use="decision-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0221828.r003</article-id>
<title-group>
<article-title>Decision Letter 1</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Reichmann</surname>
<given-names>Florian</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Florian Reichmann</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0221828" document-id-type="doi" document-type="article" id="rel-obj003" link-type="peer-reviewed-article" />
<custom-meta-group>
<custom-meta>
<meta-name>Submission Version</meta-name>
<meta-value>1</meta-value>
</custom-meta>
</custom-meta-group>
</front-stub>
<body>
<p>
<named-content content-type="letter-date">16 Aug 2019</named-content>
</p>
<p>Dietary inulin alters the gut microbiome, enhances systemic metabolism and reduces neuroinflammation in an APOE4 mouse model</p>
<p>PONE-D-19-17293R1</p>
<p>Dear Dr. Ai-Ling Lin,</p>
<p>We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.</p>
<p>Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.</p>
<p>Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <ext-link ext-link-type="uri" ns0:href="https://www.editorialmanager.com/pone/" ns0:type="simple">https://www.editorialmanager.com/pone/</ext-link>, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <email ns0:type="simple">authorbilling@plos.org</email>.</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email ns0:type="simple">onepress@plos.org</email>.</p>
<p>With kind regards,</p>
<p>Florian Reichmann, M.D., Ph.D.</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Additional Editor Comments (optional):</p>
<p>Reviewers' comments:</p>
</body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0221828.r004" specific-use="acceptance-letter">
<front-stub>
<article-id pub-id-type="doi">10.1371/journal.pone.0221828.r004</article-id>
<title-group>
<article-title>Acceptance letter</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name name-style="western">
<surname>Reichmann</surname>
<given-names>Florian</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Florian Reichmann</copyright-holder>
<license ns0:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" ns0:href="http://creativecommons.org/licenses/by/4.0/" ns0:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<related-object document-id="10.1371/journal.pone.0221828" document-id-type="doi" document-type="article" id="rel-obj004" link-type="peer-reviewed-article" />
</front-stub>
<body>
<p>
<named-content content-type="letter-date">21 Aug 2019</named-content>
</p>
<p>PONE-D-19-17293R1 </p>
<p>Dietary inulin alters the gut microbiome, enhances systemic metabolism and reduces neuroinflammation in an <italic>APOE4</italic> mouse model </p>
<p>Dear Dr. Lin:</p>
<p>I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email ns0:type="simple">onepress@plos.org</email>.</p>
<p>For any other questions or concerns, please email <email ns0:type="simple">plosone@plos.org</email>. </p>
<p>Thank you for submitting your work to PLOS ONE.</p>
<p>With kind regards,</p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>Dr. Florian Reichmann  </p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
</body>
</sub-article>
</article>